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ATTACHMENT 2 
Glossary of Acronyms 
ACA Patient Protection and Affordable Care Act 
ADAP AIDS Drug Assistance Program 
AETC AIDS Education and Training Center 
ART Antiretroviral Therapy 
ATN Adolescent Treatment Network 
BPHC Bureau of Primary Health Care 
CAPUS Care and Prevention in the United States 
CBOs Community-Based Organizations 
CDC Centers for Disease Control and Prevention 
CHAC CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and 
STD Prevention and Treatment 
CHCs Community Health Centers 
CM (Non-Medical) Case Management 
CMS Centers for Medicare and Medicaid Services 
CoAg Cooperative Agreement 
CY Calendar Year 
DASH Division of Adolescent and School Health  
DFO Designated Federal Official 
DHAP Division of HIV/AIDS Prevention  
DSTDP Division of STD Prevention 
DTBE Division of Tuberculosis Elimination 
DVH Division of Viral Hepatitis 
ECHPP Enhanced Comprehensive HIV Prevention Planning and Implementation for 
Metropolitan Statistical Areas Most Affected by HIV/AIDS 
ECPs Essential Community Providers 
EMRs Electronic Medical Records 
eUCI Encrypted Unique Client Identifier 
FACs Federal Advisory Committees 
FDA Food and Drug Administration 
FOA Funding Opportunity Announcement 
FPL Federal Poverty Level 
FQHC Federally Qualified Health Center 
GYT Get Yourself Tested 
HAB HIV/AIDS Bureau 
HBV Hepatitis B Virus 
HCV Hepatitis C Virus  
HHS U.S. Department of Health and Human Services 
HIEs Health Insurance Exchanges 
HIT Health Information Technology  
HIVMA HIV Medicine Association 
HRC Harm Reduction Coalition 
HRSA Health Resources and Services Administration 
IDUs Injection Drug Users 
IOM Institute of Medicine 
MAI Minority AIDS Initiative  
MCM Medical Case Management 
MMP Medical Monitoring Project 
MMWR Morbidity and Mortality Weekly Report  
MSA Metropolitan Statistical Area 
MSM Men Who Have Sex With Men  
NACHC National Association of Community Health Centers 
NASTAD National Alliance of State and Territorial AIDS Directors 
NCHHSTP National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention  
NHAS National HIV/AIDS Strategy 
NHB Non-Hispanic Black 
NHSS National HIV Surveillance System 
NHW Non-Hispanic White 
NIH National Institutes of Health 
NQC National Quality Center 
NQF National Quality Forum 
OAMC Outpatient Ambulatory Medical Care 
ONAP Office of National AIDS Policy 
PACHA Presidential Advisory Council on HIV/AIDS 
PACs Primary Care Associations 
PCMHs Patient-Centered Medical Homes 
PCP Primary Care Provider 
PCSI Program Collaboration and Service Integration 
PEPFAR President’s Emergency Plan for AIDS Relief 
PLWH Persons Living with HIV 
PLWHA Persons Living with HIV/AIDS 
PrEP Pre-exposure Prophylaxis 
QA/QI Quality Assurance/Quality Improvement 
RSR Ryan White Services Report 
RWP Ryan White HIV/AIDS Program 
SAMHSA Substance Abuse and Mental Health Service Administration  
SDH Social Determinants of Health 
SMS Short Messaging Services 
SPNS Special Projects of National Significance  
TAI The AIDS Institute 
UDS Uniform Data System 
USPSTF U.S. Preventive Services Task Force 
VA Department of Veterans Affairs 
VH Viral Hepatitis 
VHAP Viral Hepatitis Action Plan 
VHIG Viral Hepatitis Implementation Group 
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U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES 
CENTERS FOR DISEASE CONTROL AND PREVENTION 
HEALTH RESOURCES AND SERVICES ADMINISTRATION 
CDC/HRSA ADVISORY COMMITTEE ON HIV, 
VIRAL HEPATITIS AND STD PREVENTION AND TREATMENT 
December 11-12, 2012 
Rockville, Maryland 
DRAFT Minutes of the Meeting 
The U.S. Department of Health and Human Services (HHS), Centers for Disease Control and 
Prevention (CDC) National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
(NCHHSTP), and the Health Resources and Services Administration (HRSA) HIV/AIDS Bureau 
(HAB) convened a meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and 
STD Prevention and Treatment (CHAC).  The proceedings were held on December 11-12, 2012 
at the Hilton Rockville Hotel in Rockville, Maryland. 
Opening Session: December 11, 2012
Kevin Fenton, MD, PhD, FFPH 
Director, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Centers for Disease Control and Prevention 
CHAC Designated Federal Official, CDC 
 
Dr. Fenton conducted a roll call to determine the CHAC voting members, ex-officio members 
and liaison representatives who were in attendance.  He asked the voting members to publicly 
disclose any conflicts of interest for themselves and/or their institutions. 
 
• Kathleen Clanon, MD:  Recipient of federal grant support from HRSA/HAB 
• Angelique Croasdale, MA:  Recipient of federal funding from CDC and HRSA/HAB 
• Carlos del Rio, MD:  Recipient of federal research funding from CDC and the National 
Institutes of Health (NIH); recipient of federal Ryan White Clinic funds from HRSA/HAB; 
non-compensated Board member of the HIV Medicine Association; advisory committee 
member for Gilead and Pfizer; Board member of the International Antiviral Society-USA 
• Jeanne Marrazzo, MD, MPH:  Recipient of pharmaceutical research funding from 
Cepheid and Roche 
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• Marjorie Hill, PhD:  Recipient of federal funding from CDC, HRSA and the Substance 
Abuse and Mental Health Administration (SAMHSA); recipient of pharmaceutical funding 
from Bristol-Myers Squibb, Gilead, Merck, OraSure and Walgreens 
• Steven Johnson, MD:  Consultant to Bristol-Myers Squibb, Gilead and Merck; recipient 
of federal funding from NIH through the AIDS Clinical Trials Group; recipient of federal 
Ryan White funding from HRSA; Board member of the International Antiviral Society-
USA 
• Kenneth Mayer, MD:  Recipient of unrestricted pharmaceutical research grants from 
Gilead, Bristol-Myers Squibb and Merck; recipient of federal research funds from CDC, 
HRSA and NIH 
• Britt Rios-Ellis, PhD:  Recipient of federal funding from NIH, including the National 
Institute on Minority Health and Health Disparities 
Dr. Fenton verified that the voting members and ex-officio members constituted a quorum for 
CHAC to conduct its business on December 11, 2012.  He called the proceedings to order at 
8:34 a.m. and welcomed the participants to day 1 of the CHAC meeting. 
Dr. Fenton announced that CHAC meetings are open to the public and all comments made 
during the proceedings are a matter of public record.  He reminded the CHAC voting members 
of their individual responsibility to identify real or perceived conflicts of interest and recuse 
themselves from participating in these matters. 
Dr. Fenton announced changes to the CHAC membership since the May 2012 meeting.  He 
presented certificates of appreciation to two CDC-appointed CHAC members whose terms 
ended on November 30, 2012:  Mr. Ernest Hopkins and Dr. Kenneth Mayer.  CDC forwarded 
draft nomination packages to the White House liaison to replace the two outgoing members and 
hopes that the nominees will be formally approved in the near future.  The participants joined 
Dr. Fenton in applauding the tremendous contributions and valuable advice of Mr. Hopkins and 
Dr. Mayer during their tenures as CHAC members. 
Ms. Heather Hauck resigned as a CHAC member in July 2012 due to her new position in HRSA/ 
HAB.  Dr. Carol Brosgart resigned as a CHAC member in August 2012 due to her new position 
at the CDC Foundation to support implementation of the Viral Hepatitis Action Plan by the CDC 
Division of Viral Hepatitis.  The participants joined Dr. Fenton in thanking the two former 
members for their excellent service to CHAC. 
Ms. Kaye Hayes is the Executive Director of the Presidential Advisory Council on HIV/AIDS 
(PACHA) at the HHS Office of HIV/AIDS and Infectious Disease Policy.  She has replaced Mr. 
Christopher Bates as the ex-officio member for the HHS Office of HIV/AIDS Policy.  Dr. Stephen 
Cha is the Chief Medical Officer at the Centers for Medicare and Medicaid Services (CMS).  He 
would serve as the alternate ex-officio member for CMS in the absence of Dr. Effie George. 
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Drs. Karen Lee and Iris Mabry-Hernandez, Medical Officer for the U.S. Preventive Services 
Task Force (USPSTF), would serve as alternate ex-officio members for the Agency for 
Healthcare Research and Quality in the absence of Dr. Jennifer Croswell. 
Antigone Dempsey MEd, CHAC co-Chair 
Deputy Director, Knowledge, Transfer and Technical Assistance 
HIV/AIDS Lead, Altarum Institute 
Ms. Dempsey joined Dr. Fenton in welcoming the participants to the CHAC meeting and opened 
the floor for introductions (Attachment 1: List of Participants).  She provided an overview of the 
format and organizational structure of CHAC meetings for the benefit of the new members.  For 
each presentation, summary sheets are distributed to the members in advance of meetings that 
describe the background, key issues for action and advice requested from CHAC.  The agenda 
is developed based on the theme for each meeting. 
The first meeting of the year is held in the spring in Atlanta and primarily is devoted to 
“prevention” presentations by CDC.  The second meeting of the year is held in late fall/early 
winter in the Washington, DC area and primarily is devoted to “care and treatment” 
presentations by HRSA. 
The CHAC business session was revamped to make the process of developing resolutions 
(e.g., policy statements) and recommendations (e.g., action-oriented items) more productive 
and efficient.  CHAC members are asked to volunteer as “champions” to draft the wording of 
and provide leadership for the resolution/recommendation.  The champions present the draft 
language during the business session for CHAC’s review, discussion, proposed amendments 
and formal vote.  However, caution is taken in making resolutions/recommendations because 
the champions and other CHAC members contribute their individual time and effort outside of 
meetings to address these topics. 
Ms. Dempsey announced that the meeting would be bittersweet due to Dr. Fenton’s departure 
from CDC as the NCHHSTP Director and the CHAC Designated Federal Official (DFO).  She 
asked the participants to join her in honoring Dr. Fenton’s outstanding accomplishments over 
his seven-year tenure. 
Jeanne Marrazzo, MD, MPH, CHAC co-Chair 
Professor of Medicine, Harborview Medical Center 
University of Washington 
Dr. Marrazzo added that the meeting format was revised to shorten the number and length of 
presentations and allow more time for CHAC to discuss key issues, consider future agenda 
items, and draft resolutions/recommendations.  She confirmed that the CHAC co-Chairs and 
DFOs would continue to solicit input from the members to further enhance the structure and 
overall process of meetings. 
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Deborah Parham Hopson, PhD, RN, FAAN 
Associate Administrator, HIV/AIDS Bureau 
Health Resources and Services Administration 
CHAC Designated Federal Official, HRSA 
Dr. Parham Hopson joined her colleagues in welcoming the participants to the CHAC meeting.  
She explained that HRSA is continuing to strengthen its understanding of the implications of the 
Affordable Care Act (ACA) on all programmatic activities across the agency. 
Dr. Parham Hopson pointed out that biographical sketches of four new HRSA-appointed CHAC 
members were included in the meeting packets.  She asked the participants to join her in 
formally welcoming the new members: 
• Bruce Agins, MD, MPH: Medical Director, AIDS Institute, New York State Department of 
Health 
• Tommy Chesbro, MHR, CSE: Owner, Chesbro Consulting, LLC 
• Angelique Croasdale, MA: Project Manager, Ryan White Part A Program, City of 
Hartford 
• Jennifer Kates, PhD: Vice President/Director, Global Health and HIV Policy, Kaiser 
Family Foundation 
HRSA/HAB Associate Administrator’s Report
Deborah Parham Hopson, PhD, RN, FAAN 
Associate Administrator, HIV/AIDS Bureau 
Health Resources and Services Administration 
CHAC Designated Federal Official, HRSA 
Dr. Parham Hopson covered the following topics in her Associate Administrator’s report to 
CHAC.  HAB held the Ryan White All Grantee Meeting on November 27-29, 2012 with a theme 
of Navigating a New Era in Care and a focus on technical assistance, administrative oversight, 
fiscal management and clinical HIV care.  In addition to 214 workshops, the All Grantee Meeting 
also featured a “Meet the CHAC” session. 
The Government Accounting Office conducted investigations of several HRSA bureaus in 2012, 
but the two investigations that were most relevant to HAB focused on monitoring of Parts A and 
B grantees and sub-grantees of the Ryan White HIV/AIDS Program (RWP) and the Minority 
AIDS Initiative (MAI).  HAB released the 2012 Ryan White HIV/AIDS Program Progress Report: 
Ahead of the Curve on its website. 
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HAB is continuing to monitor the implementation of ACA to ensure a seamless transition into 
ACA for RWP clients who will receive expanded coverage.  In this effort, HAB is educating RWP 
providers and programs on ACA opportunities for persons living with HIV (PLWH) at state and 
county levels.  Although HHS and HRSA are taking steps to determine changes in RWP that 
might be driven by ACA, full implementation of ACA will not eliminate the need for RWP. 
In October 2009, RWP was reauthorized through September 2013.  HAB launched an RWP 
planning strategy that included extensive engagement of external stakeholders.  HAB identified 
several potential options for reauthorization.  For example, option 1 would be to take no action, 
allow the reauthorization to expire, and continue RWP based on an appropriation.  Option 2 
would be to slightly modify RWP through reauthorization or an appropriation.  Option 3 would be 
to significantly change RWP through full reauthorization. 
To solicit feedback from key stakeholders (e.g., grantees, PLWH and advocates) on the future 
of RWP in terms of adopting one of the three options, HAB hosted four virtual listening sessions 
in the South, Northeast, West and Midwest regions in July 2012; opened a portal on the 
Regulations.gov website for stakeholders to submit written comments to HAB; and held three 
meetings with national partners.  
All of the comments submitted by stakeholders are available on the HAB website, but major 
themes were identified.  Strong support was expressed for continuation of RWP.  The need to 
increase the focus on continuity of care, retention in care, and streamlined wraparound and 
support services was emphasized.  Concerns were raised about the impact of variability in ACA 
implementation on different jurisdictions.  The need for increased flexibility was emphasized in 
terms of the 75%/25% requirement for core/support services, payer of last resort and the 
administrative cap.  A waiver process has been established. 
HAB’s priorities in 2013 will aim to advance the goals of the National HIV/AIDS Strategy (NHAS) 
and help to achieve an AIDS-free generation.  HAB’s activities in 2013 to accomplish this goal 
will include engaging and retaining PLWH in care; refining and publishing RWP client-level data; 
preparing HAB staff and RWP grantees for full implementation of ACA; and engaging in 
discussions regarding continuation of RWP and the President’s Emergency Plan for AIDS Relief 
(PEPFAR). 
HAB will continue to focus on its existing activities in 2013, including Quality Initiatives, Special 
Projects of National Significance (SPNS), the UCARE4LIFE initiative to reach adolescents living 
with HIV through texting, HIV workforce studies (e.g., Medical and Nursing Education 
Partnership Initiatives), and dissemination and inclusion of lessons learned between global and 
domestic programs.  HAB will continue to fund and monitor RWP and PEPFAR grantees. 
HAB data collected from the Ryan White Services Report (RSR) estimated that 546,156 clients 
received at least one RWP-funded service in calendar year (CY) 2010.  By gender, ~69% of 
RWP clients were male, ~31% were female, and <1% were transgender.  By race/ethnicity, 
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~47% of RWP clients were non-Hispanic black (NHB), ~28% were non-Hispanic white (NHW), 
and ~22% were Hispanic.  By age, ~1 in 3 RWP clients were in the 40-49 age group, 24% were 
in the 50-59 age group, and 19% were in the 30-39 age group. 
HAB developed 62 HIV performance measures covering different aspects of care and treatment 
to ensure that RWP grantees deliver the highest quality care to clients.  RWP grantees can 
select specific performance measures to implement, but HAB has submitted five measures for 
national endorsement through the National Quality Forum (NQF): 
1. frequency of HIV medical visits, 
2. gaps in HIV medical care, 
3. prescriptions of HIV antiretroviral therapy (ART), 
4. HIV viral load suppression, and 
5. newly enrolled in HIV medical care. 
After the NQF Infectious Disease Endorsement Maintenance Steering Committee determined 
that measures 1-4 were suitable for endorsement, the measures were forwarded to the NQF 
Consensus Standards Approval Committee for review.  HAB is collaborating with CMS and the 
HHS Office of the National Coordinator for Health Information Technology to include measures 
1-4 in Stage 3 Meaningful Use criteria (e.g., improved outcomes) that will be launched in 2016.  
All 62 HIV performance measures can be viewed at: 
http://hab.hrsa.gov/deliverhivaidscare/habperformmeasures.html. 
HAB awarded a five-year cooperative agreement (CoAg) to the New York State AIDS Institute 
over the project period from August 2012 to June 2017 to conduct the National Quality Center 
(NQC).  The NQC infrastructure will be used to provide training and technical assistance, quality 
management coaching, learning collaboratives for 135 grantees representing 38 states, and the 
In+Care Campaign (www.incarecampaign.org). 
HAB funded three new SPNS Initiatives in 2012:  (1) “Enhancing Access to and Retention in 
HIV Primary Care for Transgender Women of Color” (2012-2017); (2) “Building a Medical Home 
for Multiple Diagnoses HIV-Positive Homeless Populations” (2012-2017); and (3) “Replication of 
Public Health Information Exchange to Support Engagement in HIV Care” (2012-2015).  If the 
FY2013 President’s budget request is approved, RWP funding will slightly increase from ~$2.4 
billion in the FY2012 enacted budget to ~$2.5 billion. 
Dr. Parham Hopson concluded her update by announcing that HAB has expanded its staff with 
new Project Officers, Branch Chiefs and other personnel to improve the delivery of services to 
RWP grantees. 
• Dr. Rupali Doshi:  Medical Officer, Office of the Associate Administrator 
• Cynthia Grubbs:  Acting Director, Office of Operations and Management & Executive 
Officer 
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• Heather Hauck:  Director, Division of State HIV/AIDS Programs 
• Dr. Polly Ross:  Deputy Director, Division of Community HIV/AIDS Programs 
CDC/NCHHSTP Director’s Report
Kevin Fenton, MD, PhD, FFPH 
Director, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Centers for Disease Control and Prevention 
CHAC Designated Federal Official, CDC 
Dr. Fenton covered the following topics in his Director’s report to CHAC.  At the agency level, 
several changes in CDC’s leadership have occurred over the past few months.  Dr. Rima 
Khabbaz, Deputy Director for Infectious Diseases and Director of the Office of Infectious 
Diseases at CDC, will serve as the Acting Director of NCHHSTP over the next 3-6 months until 
Dr. Fenton’s permanent replacement has been officially appointed.  Dr. Thomas Frieden, 
Director of CDC, has made a strong commitment to launch and complete the national search for 
the new NCHHSTP Director as quickly as possible. 
Dr. John Douglas, the NCHHSTP Chief Medical Officer, will serve as the Acting DFO for CHAC 
during the national search.  The new NCHHSTP Director could serve as the CHAC DFO for 
CDC or designate senior staff to fill this role.  Dr. Fenton encouraged the CHAC members to 
submit names of potential candidates to CDC. 
Dr. Anne Schuchat is serving as the Acting Director for the CDC Center for Global Health while 
a search is being conducted to permanently replace Dr. Kevin DeCock in this position.  Dr. 
Denise Cardo is serving as the Acting Director of the CDC Office of Surveillance, Epidemiology 
and Laboratory Services to permanently replace Dr. Stephen Thacker who retired from this 
position. 
CDC is operating under a continuing resolution through March 27, 2013, but the continuing 
resolution does not address the January 2, 2013 sequester mandated by the 2011 Budget 
Control Act.  If this issue is not resolved in a timely manner, CDC will closely collaborate with its 
federal partners within and outside of HHS to implement measures to mitigate the impact. 
CDC recently published a Vitalsigns Report on HIV among youth in the United States with 
several key findings.  First, one in four new HIV infections occurs in youth 13-24 years of age.  
Second, ~1,000 youth per month were infected with HIV in 2010.  Third, 60% of youth who are 
living with HIV have no knowledge of their infection. 
The Vitalsigns Report also highlights major challenges with the concentration of HIV among 
young gay/bisexual men and young men who have sex with men (MSM) of color, particularly 
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African American MSM.  CDC will soon release new data on HIV incidence in the United States 
to provide more details on trends in new infections and highlight the disproportionate burden of 
disease among youth.  The Vitalsigns Report is available at: 
www.cdc.gov/vitalsigns/pdf/2012-11-27-vitalsigns.pdf. 
At the National Center level, NCHHSTP made several key accomplishments to support its six 
cross-cutting priorities to implement a more integrated and holistic approach to preventing HIV, 
STD, viral hepatitis and TB.  Priority 1 is “program collaboration and service integration” (PCSI).  
Data Security and Confidentiality Guidelines for HIV, Viral Hepatitis, STD and TB were released 
(www.cdc.gov/nchhstp/programintegration/docs/PCSIDataSecurityGuidelines.pdf). 
An integrated funding opportunity announcement (FOA) was released for Pacific Island 
jurisdictions to eliminate the burden of reporting and managing data across multiple FOAs.  A 
new Internet-based “Atlas” was launched to increase public access to NCHHSTP data across 
programs (www.cdc.gov/nchhstp/atlas).   
Collaborations were established with multiple HHS agencies to publish a Morbidity and Mortality 
Weekly Report (MMWR) article summarizing guidelines and recommendations on integrated 
approaches for the prevention and control of HIV, STDs, viral hepatitis and TB for persons who 
illicitly use drugs (www.cdc.gov/mmwr/pdf/rr/rr6105.pdf).  A PCSI consultation was held to 
discuss surveillance systems for HIV, STDs, TB and viral hepatitis; explore new opportunities 
with ACA and health information technology (HIT); and determine approaches for dissemination 
of strategic information for infectious diseases. 
Priority 2 is “promotion of health equity and reduction in health disparities.”  Language was 
included in all new FOAs that will require grantees to address structural and social determinants 
of health (SDH) in all NCHHSTP-funded activities.  A special Public Health Reports Supplement 
was published focusing on data systems and their use in addressing and monitoring SDH 
related to the four infectious diseases. 
Efforts are underway to build capacity with internal CDC staff and external partners to ensure 
health equity and SDH are incorporated into programming.  The NCHHSTP SDH website was 
enhanced.  The eighth year of NCHHSTP’s “Third Thursday Lunch” and “Learn Health Equity” 
series was completed. 
Priority 3 is “prevention through healthcare.”  A summary was released on the consultation, 
“Prevention Through Healthcare: Enhancing Health Departments’ Preparedness and Response” 
(www.cdc.gov/nchhstp/PreventionThroughHealthcare/index.htm).  A collaboration was formed 
with HRSA to support partnerships between state health departments and Community Health 
Centers (CHCs) to improve the quality and coordination of care for persons living with HIV/ 
AIDS, viral hepatitis, STDs or TB.  An internal caucus recently was held to explore strategies for 
CDC and its grantees to become more active in the nexus between public health and primary 
care. 
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Priority 4 is “partnerships.”  New health communication and social marketing campaigns were 
launched.  The “Get Yourself Tested” (GYT) Campaign was updated and generated a 10% 
increase in testing at STD clinics.  Year 2 of the “Act Against AIDS” Campaign had >1.6 billion 
media impressions.  The new “Testing Makes Us Stronger” Campaign” was launched.  The 
“KNOW MORE HEPATITIS” Campaign is currently under development. 
Disease-specific strategic initiatives at the federal level included coordination on implementation 
of NHAS and collaborations with multiple HHS operating divisions on the Viral Hepatitis Action 
Plan (VHAP).  Public-private partnerships included collaboration with the CDC Foundation on 
the National Viral Hepatitis Action Coalition, CDC’s Sexual Health Coalition, and the National 
Chlamydia Coalition’s launch of the web-based Chlamydia Resource Exchange. 
Priority 5 is “global health protection and health systems.”  A demonstration project was initiated 
to assess the feasibility of integrated antenatal services, including maternal syphilis testing.  A 
collaboration was established with the CDC Division of Global HIV/AIDS to assess HIV 
incidence in Western Kenya to improve linkage to HIV care. 
A collaboration was formed with the World Health Organization to implement a Global Youth 
Risk Behavior Surveillance System in developing countries.  Leadership was provided on 
research that identified a screening approach to increase the diagnosis of TB in PLWH.  
Training on TB infection control was provided to >100 staff in India, Vietnam, Cambodia and 
Thailand. 
Priority 6 is “workforce development and capacity building.”  The “Coaching and Leadership” 
Initiative was piloted to build leadership, management, administrative and supervision skills of 
NCHHSTP team leaders.  The first NCHHSTP speed-mentoring event was hosted with a theme 
of Developing Leadership.  The “Federal Job Shadowing Day for Historically Black Colleges and 
Universities in Georgia” was held in March 2012.  The “5th Annual NCHHSTP Summer Fellows 
Forum” was hosted with participation by >60 fellows. 
NCHHSTP was extremely pleased with the outstanding contributions and coordination of federal 
partners across HHS and external stakeholders that resulted in the tremendous success of the 
XIX International AIDS Conference in July 2012.  NCHHSTP’s strong role at the conference 
included leading or co-leading three sessions, presenting >50 poster sessions, and making 10 
oral presentations and oral poster sessions that highlighted the syndemics of HIV with STDs, 
hepatitis and TB. 
CDC’s media outreach efforts to support the conference produced 151 unique media stories 
and 1 billion media impressions.  Overall, the conference provided an opportunity for HHS at the 
department level and CDC at the agency level to become involved in a new national 
conversation on HIV/AIDS. 
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At the division level, the NCHHSTP Division of HIV/AIDS Prevention (DHAP) awarded year 1 
funds in January 2012 for the five-year health department CoAg.  The awards were based on 
the geographic burden of HIV.  The new “Let’s Stop HIV Together” Campaign was launched and 
featured PLWH, their friends and families to raise HIV awareness and promote an anti-stigma 
culture.  The “Take Charge. Take the Test” Campaign aimed at African American women is 
included in this initiative. 
DHAP used MAI funds from the HHS Secretary to award $44.2 million under the three-year 
“Care and Prevention in the United States” (CAPUS) demonstration project to expand HIV 
prevention services for minority communities with a high prevalence of HIV.  The project also 
will address social and structural drivers that influence the treatment cascade to produce a 
greater impact.  DHAP is collaborating with HRSA to update guidelines on incorporating HIV 
prevention into medical care of PLWH and on post-exposure prophylaxis. 
The NCHHSTP Division of Adolescent and School Health (DASH) recently released the new 
“Parent Engagement” resource to help schools to increase the engagement of parents in 
promoting positive health behaviors: 
(www.cdc.gov/healthyyouth/adolescenthealth/pdf/parent_engagement_factsheet.pdf). 
DASH published an MMWR article, “HIV, Other STD and Pregnancy Prevention Education in 
Public School Secondary Schools-45 States, 2008-2010.”  In terms of state trends in the 
percentage of secondary schools that taught all essential topics from 2008 to 2010, the article 
reported a decline in middle schools in 11 states, a decline in high schools in 1 state, and an 
increase in high schools in 2 states (www.cdc.gov/mmwr/pdf/wk/mm6113.pdf). 
The NCHHSTP Division of Viral Hepatitis (DVH) issued new hepatitis C virus (HCV) screening 
guidelines in the August 17, 2012 edition of the MMWR.  The guidelines recommended one-
time hepatitis screening for all persons in the United States born in 1945-1965.  The CDC 
Advisory Committee on Immunization Practices issued recommendations in the December 23, 
2011 edition of the MMWR that supported hepatitis B virus (HBV) vaccination for adults with 
diabetes.  DVH led the successful launch of the first “National Hepatitis Testing Day” that 
featured >100 testing events across the country to help identify and link infected persons to 
necessary treatment. 
The NCHHSTP Division of STD Prevention (DSTDP) published revised guidance for treatment 
of gonorrhea in an August 2012 MMWR article.  The purpose of the guidance was to respond to 
increased drug resistance and raise awareness of drug resistance.  DSTDP conducted several 
activities to support STD Awareness Month, including participating in the GYT Campaign; 
launching a web page to educate physicians on discussing STDs and testing with their patients; 
and hosting the “STD Awareness” blog (www.AIDS.gov).  DSTDP played a key role in launching 
the new Global Congenital Syphilis Partnership. 
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The NCHHSTP Division of Tuberculosis Elimination (DTBE) issued new recommendations in 
the MMWR on treating latent TB, “Use of an Isoniazid-Rifapentine Regimen with Direct 
Observation to Treat Latent Mycobacterium tuberculosis Infection.”  DTBE issued the Reported 
Tuberculosis in the United States publication that reported 10,528 new TB cases in the United 
States in 2010 and the 19th consecutive year of decline in new cases.  DTBE launched a new 
TB website in Spanish. 
Dr. Fenton concluded his update by confirming that the meeting would be bittersweet due to his 
departure from CDC as the NCHHSTP Director over the past seven years.  However, he noted 
that his departure is timely because all of NCHHSTP’s leadership positions currently are filled 
with permanent staff.  NCHHSTP’s most recent permanent appointments are Dr. Wayne Duffus 
(Associate Director for Health Equity) and Mr. Thomas Sukalac (Associate Director for 
Informatics). 
Dr. Fenton emphasized that his role as the CHAC DFO would be one of the duties he would 
miss the most as the NCHHSTP Director.  Over his seven-year tenure, CHAC’s advice and 
support have been immensely helpful and played a critical part in strengthening the efficiency 
and effectiveness of his leadership role at CDC.  CHAC also has given CDC critical and 
constructive input and valuable guidance on future directions.  He thanked both the current and 
former CHAC members for their diligent efforts and tremendous contributions.   
Ms. Dempsey and Dr. Marrazzo moderated CHAC’s discussion with Drs. Parham Hopson and 
Fenton on the HRSA and CDC updates.  The discussion topics included: 
• the critical need to continue RWP in an ACA era based on outcomes in Massachusetts 
(e.g., a decrease in the number of new HIV infections and adherence to performance 
measures by CHCs); 
• key priorities, activities and focus areas of the new NCHHSTP Director in the first two 
years of assuming this position; 
• the need for additional investments by HHS agencies other than CDC and HRSA to truly 
integrate prevention and care/treatment in jurisdictions across the country; 
• reasons for the minimal uptake of pre-exposure prophylaxis (PrEP) for HIV prevention 
despite CDC’s evidence-based guidance and approval of PrEP by the Food and Drug 
Administration (FDA); 
• interventions, information and programs (e.g., school-/out-of-school-based activities, 
social media campaigns and updated messages) to effectively reach children during 
their transition to youth/adolescents; address HIV prevention in new groups of young 
persons in a proactive and ongoing manner; and achieve the goal of an HIV-free 
generation; 
• strategies to enhance coordination between state health departments and CHCs to 
improve testing and linkage to care/treatment for PLWH and newly diagnosed cases in 
jurisdictions across the country; 
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• HRSA’s plans to allocate funds to rural states that have limited services and significant 
populations of PLWH not in care, but will opt-out of Medicaid expansion under ACA; 
• CDC’s engagement of the U.S. Department of Education, particularly for DASH activities 
and implementation of NHAS in collaboration with other federal agencies; and 
• HAB’s client-level data on the payer status and income breakdown of RWP clients to 
determine the future role of RWP and implications of ACA implementation, particularly 
for the underinsured patient population. 
Drs. Parham Hopson and Fenton made several follow-up remarks in response to some of the 
topics CHAC raised during the discussion.  In terms of priority issues for the new NCHHSTP 
Director in the first two years, attention should be given to three major areas.  First, the 
momentum NCHHSTP has established over the past seven years under Dr. Fenton’s leadership 
should be maintained.  The focus should be placed on initiatives that have played a significant 
role in driving health impact and helping NCHHSTP to become more efficient and effective. 
Second, syndemic and holistic approaches (e.g., PCSI, social/structural determinants of health, 
and a broad sexual health framework) that have been developed and promoted over the past 
seven years should be sustained over time.  The new NCHHSTP Director should ensure that 
the divisions do not return to the historical approach of operating independently in silos. 
In addition to the disease itself, individuals with the disease along with their families and 
communities also should be considered in all NCHHSTP activities.  Moreover, the new CAPUS 
initiative should be widely promoted to help NCHHSTP advance from considering syndemics 
and social/structural determinants of health as theories to actually incorporating these issues 
into prevention programming. 
Third, NCHHSTP should continue to leverage opportunities under new and existing policies of 
the Administration (e.g., ACA and NHAS).  NCHHSTP should conduct environmental scans and 
immediately take action on these initiatives. 
In terms of truly integrating prevention and care/treatment, the federal partners have engaged in 
extensive discussions on the possibility of deploying CDC staff to HRSA and HRSA staff to 
CDC.  This approach would allow CDC and HRSA to share information in a more efficient 
manner and become more knowledgeable of the organizational culture of the other agency.  
However, efforts to identify CDC staff with a willingness to relocate to the Washington, DC area 
and HRSA staff with a willingness to relocate to Atlanta have been difficult.  In the interim, CDC 
and HRSA will continue to participate on joint workgroups and collaborate on other activities, but 
the agencies welcome input from CHAC on additional ideas to make further progress in this 
area. 
The integration of public health and primary care continues to be an extremely important issue 
for both CDC and HRSA.  However, CHCs increasingly are overwhelmed and overburdened by 
meeting the diverse needs of their clients:  infectious diseases (e.g., HIV, STDs and viral 
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hepatitis); chronic diseases (e.g., obesity, physical exercise and nutrition); and other needs 
(e.g., mental health, substance abuse, homelessness and sexual identity). 
Due to the competing priorities of CHCs, CDC and HRSA have identified four action steps to 
emphasize the importance of integrating public health and primary care to achieve a greater 
impact on infectious diseases.  First, specific components in an “integrated relationship” for HIV, 
STDs and viral hepatitis should be clearly defined and streamlined for CHCs.  Second, funding 
should be allocated to CHCs to replicate best/promising practices and lessons learned in 
integration. 
Third, training resources should be provided for CHCs to learn more about the cultures, 
business practices and standard operating procedures of both public health and primary care.  
Fourth, CHCs should be funded to conduct demonstration projects to gather data on public 
health/primary care integration. 
In terms of strategies to more effectively reach youth, NCHHSTP will develop and implement a 
cross-center strategic plan for youth HIV/STD prevention and sexual health in FY2013 based on 
recommendations from the External Expert Review that was held in March 2012.  In this effort, a 
“life course” approach will be taken to determine the aging process of the youth cohort over time 
and the impact of NCHHSTP’s sexual health and HIV/STD prevention activities on youth.  
Results from the initiative will be used to coordinate activities, fill gaps, and identify opportunities 
in this area as the youth cohort ages. 
CHAC was extremely impressed by the high level of productivity of CDC and HRSA over the 
past six months, including their individual activities and joint efforts as federal partners.  Several 
members particularly thanked HAB for its tremendous outreach in hosting four regional listening 
sessions for communities and stakeholders to provide input on RWP reauthorization. 
CHAC made a number of comments and suggestions for CDC and HRSA to consider in their 
ongoing efforts to further advance HIV, viral hepatitis and STD prevention and treatment. 
• CDC and HRSA should explore the possibility of including language in FOAs that would 
require applicants to demonstrate coordination and collaboration between prevention 
and care/treatment as a condition of funding. 
• CDC and HRSA should elevate discussions on the uptake of PrEP from an agency level 
to a higher departmental level at HHS.  If CDC has no funds to support implementation 
of PrEP, for example, HHS could direct HRSA to conduct a demonstration of project of 
PrEP based on its mandate to focus on HIV-infected persons through RWP grantees. 
• An integrated prevention package that includes PrEP and ART should be developed for 
specific populations and widely marketed to providers. 
• CDC’s recent publication on HIV diagnoses among MSM by metropolitan statistical area 
(MSA) reported that 10 MSAs account for >50% of all new HIV infections in the country.  
These data should be used to further promote integration in all jurisdictions and mobilize 
  
 
DRAFT Meeting Minutes: CDC/HRSA Advisory Committee on 
HIV, Viral Hepatitis and STD Prevention and Treatment 
December 11-12, 2012  ║ Page 14 
resources across the federal government to reach this disproportionately impacted 
population. 
• CHAC and PACHA should issue a joint statement to emphasize that one of the most 
important areas of focus for the new NCHHSTP Director should be to formally 
institutionalize SDH in FOAs and other activities to ensure this framework is sustained 
over time. 
Overview of the Impact of the Affordable Care Act on HRSA/HAB
Rebecca Slifkin, PhD 
Director, Office of Planning, Analysis and Evaluation 
Health Resources and Services Administration 
Advice Requested from CHAC by HRSA: 
• What are the main issues of concern around ACA implementation that need to be 
addressed? 
• What are the critical lessons learned from states that already have expanded insurance 
coverage? 
• What technical assistance will RWP providers need to be able to participate in both 
Medicaid expansions and plans on the exchanges?  Do all providers have the necessary 
billing systems established for private insurance?  What capacity issues exist?  What are 
the anticipated issues with provider contracting? 
• What strategies can be implemented to reach and enroll eligible RWP populations and 
PLWHA in insurance?  What approaches can be applied to specifically reach homeless 
populations? 
• How can HRSA coordinate with CDC to ensure that new cases are directed both to care 
and insurance coverage? 
• How can CHAC members serve as vehicles for delivery of outreach and enrollment 
activities and materials? 
• What resources do CHAC members need in terms of educational/outreach materials and 
training to facilitate enrollment? 
Dr. Slifkin presented an overview of the impact of ACA on RWP and PLWHA.  ACA will 
dramatically increase health insurance coverage for PLWHA due to several changes.  Insurers 
will be prohibited from discriminating against persons with preexisting conditions.  States will 
have an option to expand Medicaid coverage to all U.S. citizens and legal residents who have 
lived in the United States for at least five years up to 133% of the Federal Poverty Level (FPL). 
 
Medicaid matching funds to states by the federal government will be 100% in years 1-2 of ACA 
and 90% thereafter.  However, states that elect not to expand Medicaid coverage to the full 
133% will not be eligible for the 100% federal match.  These states will continue to receive their 
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regular federal matching rate.  Decisions on whether and when to implement Medicaid 
expansions will be at the discretion of each state. 
Health Insurance Exchanges (HIEs) will be available for persons with incomes that are too high 
for Medicaid expansions.  These persons will be able to purchase affordable private insurance, 
but low-income persons can apply for federal assistance for their HIE insurance premiums up to 
400% of the FPL and HIE co-payments/deductibles up to 250% of the FPL.  This change will 
affect the extent to which AIDS Drug Assistance Program (ADAP) funds can be used for 
financial assistance for insurance premiums. 
States that plan to independently operate HIEs must submit their applications to CMS by 
December 14, 2012.  States that plan to jointly operate HIEs with the federal government must 
submit their applications to CMS by mid-February 2013.  The federal government will operate 
HIEs for states that do not submit applications in either of these two categories.  HIE coverage 
will be initiated on January 1, 2014, but HIE enrollment will begin in October 2013. 
HRSA is aware that multiple sources must be engaged to address diverse and complex issues 
related to ACA, including HHS and HRSA bureaus at the federal level, states and external 
stakeholders.  In support of this effort, HAB convened stakeholder meetings with RWP grantees 
and HRSA is continuing to communicate with state partners to gather and analyze information 
and identify potentially problematic areas. 
HRSA is compiling lessons learned and experiences related to state Medicaid expansions that 
were implemented by California, Colorado and Massachusetts.  HRSA is reviewing CMS’s draft 
ACA regulations and is using these opportunities to propose revisions based on its statutory 
requirements.  Based on its analyses to date, HRSA has identified a number of areas that will 
need legal decisions or policy guidance to ensure that RWP is closely aligned with ACA.  These 
issues include continuity of care, access to providers with experience in treating PLWHA, and 
available resources for providers to enroll clients in ACA. 
HRSA recognizes that extensive outreach will be needed for RWP clients to understand their 
eligibility status and options to enroll in ACA and for RWP providers to deliver care and 
treatment in accordance with HRSA’s payer of last resort requirements.  CMS recently 
announced that HHS will collaborate with states and other stakeholders in developing an 
outreach strategy for consumers.  The components of the strategy will include a navigator 
program and additional assistance through face-to-face sessions, call centers and Internet 
resources. 
CMS will begin disseminating ACA outreach materials by the end of January 2013, but HRSA 
also will distribute information on ACA specifically for its target populations.  HRSA has taken 
steps to ensure that its future ACA materials will be distributed in concert with CMS materials to 
avoid dissemination of conflicting information.  Most notably, HRSA serves on the HHS-wide 
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ACA Communication Workgroup and regularly meets with the CMS Office of Communication to 
discuss communication strategies and the delivery of common messages. 
HRSA’s key priority at this time is to offer tools, technical assistance, resources and other 
necessary support to providers to have a strong voice in ACA implementation and develop 
contracts with Medicaid expansions and HIE providers, and other guidance to encourage 
providers to develop contracts that will help RWP clients continue care and treatment with their 
existing providers in local jurisdictions. 
HRSA’s other major focus area at this time is access to prescription drugs.  All Medicaid 
expansions and HIE plans will be required to cover prescription drugs.  This issue has not been 
fully resolved in ACA to date, but HRSA still will be required to ensure that RWP clients are 
“medically whole.”  HRSA is continuing to collaborate with CMS on coordinating ADAP in an 
ACA environment and addressing potential changes that could occur with Medicaid expansions. 
Ms. Dempsey moderated CHAC’s discussion with Dr. Slifkin on the impact of ACA on RWP and 
PLWHA.  The discussion topics included: 
• the need for HRSA to provide RWP grantees with clear language and guidance on the 
ACA regulation related to “Essential Community Providers” (ECPs); 
• the need for HRSA to review best practices and models to directly engage, educate and 
empower PLWH in its ACA implementation activities; and 
• incomes outside of the ACA regulations:  (1) low-income PLWH who still will not be 
eligible for Medicaid under the expansions and (2) PLWH outside of the Medicaid 
expansion threshold who will be unable to afford HIE insurance premiums. 
CHAC made several comments and suggestions for HRSA to consider in its ongoing efforts to 
provide guidance to grantees on the impact of ACA on RWP and PLWHA. 
• HRSA’s plan to provide RWP grantees with experiences and lessons learned from state 
Medicaid expansions is a sound approach.  The following guidance should be provided 
to RWP clinics and providers based on the California model: 
o complete the process to become a Federally Qualified Health Center (FQHC); 
o complete the process to register with local Medicaid managed programs as a primary 
care provider (PCP) or specialist; 
o complete the process to register with the 340B Drug Pricing Program at the HRSA 
Office of Pharmacy Affairs; 
o make efforts to replicate and/or link to chronic disease programs until payment 
reform with team-based care and patient-centered medical homes (PCMHs) is fully 
implemented and reimbursed nationally; and 
o responsibly share data with other state programs on HIV-infected patients, including 
ADAP data, to avoid interruption in treatment. 
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• HRSA and CMS should allocate funding at this time to build the capacity of academic 
centers in serving as the national infrastructure to recruit and train the next generation of 
HIV providers.  This initiative would help to assure retention of the PCMH model for HIV 
care that was established by RWP. 
• Efforts by the federal government to disseminate ACA information have been difficult 
and time-consuming to date due the complexity, regulatory burden and overall 
magnitude of this issue.  However, the agencies should take advantage of existing social 
media platforms and other communication systems to rapidly deliver basic information to 
RWP grantees and PLWH.  Although federal agencies can only distribute materials that 
have undergone the formal clearance and approval process, factual messages in 
laymen’s terms can be delivered in the interim to alleviate the fears of PLWH and the 
general public.  The agencies should engage CHAC members and other stakeholders in 
a grassroots effort to develop and launch a general information campaign with basic 
messages that would be easily understood by the public (e.g., “ACA prohibits insurers 
from discriminating against you if you have a preexisting condition.”  “Here are 10 
reasons why ACA is important to you.”).  The federal agencies also should establish a 
toll-free hotline for the public as a companion to the general information campaign.  
Moreover, journalists should be engaged to convey key ACA messages through the 
media. 
Dr. Slifkin appreciated CHAC’s in-depth discussion on the impact of ACA on RWP and PLWHA, 
but she noted that the comments and suggestions did not directly respond to HRSA’s request 
for advice.  She asked the members to review the questions HRSA posed to CHAC and provide 
more focused feedback, particularly in the context of best practices, lessons learned and 
experiences that could be applied to ACA implementation.  She confirmed that the list of “ACA 
Frequently Asked Questions” HHS released on the previous day would be circulated to CHAC 
as a resource in responding to the questions. 
Dr. Rima Khabbaz joined the meeting and announced that she would begin serving as the 
Acting Director of NCHHSTP on January 2, 2013.  During her acting role over the next few 
months, she looked forward to collaborating with NCHHSTP leadership and CHAC to ensure 
that the solid strategic direction Dr. Fenton established was maintained.  She confirmed that 
NCHHSTP’s leadership and participation in national strategies and its momentum of various 
programs, activities and efforts across CDC would be sustained and advanced. 
Dr. Khabbaz emphasized that the national search to identify and officially appoint the new 
NCHHSTP Director in a timely manner is one of CDC’s key priorities.  CDC is extremely 
pleased that Dr. Marrazzo agreed to serve on the search committee to ensure CHAC’s voice is 
heard in these deliberations.  Because CDC has fast-tracked the search process, Dr. Khabbaz 
encouraged the CHAC members to submit names of potential candidates with the necessary 
skills, expertise and qualities to serve as the next NCHHSTP Director.  She noted that CDC 
expects to post the position announcement in January 2013. 
 Overview of Ryan White HIV/AIDS Program Client-Level Data
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Deborah Isenberg, MPH, CHES 
Chief, Data Management Branch, Division of Science and Policy/HAB 
Health Resources and Services Administration 
 
Faye Malitz, MS 
Senior Data Advisor, Division of Science and Policy/HAB 
Health Resources and Services Administration 
Advice Requested from CHAC by HAB: 
• What is CHAC’s input on analytic priorities for RWP client-level data? 
 
Ms. Isenberg and Ms. Malitz presented an overview of the preliminary 2010 Ryan White 
Services Report (RSR) client-level data.  Outpatient ambulatory medical care (OAMC), medical 
case management (MCM) and non-medical case management (CM) funded providers were 
required to report client-level data for the first time in 2009.  This requirement was expanded to 
include all RWP-funded providers in 2010.  The Ryan White Data Report (RDR), which collected 
aggregate data from funded providers, was retired in 2010.  
 
The client-level file should contain one record for each client who received an RWP-funded 
service during the reporting period.  Each client record must include the client’s encrypted 
unique client identifier (eUCI).  Each record may include up to 66 data elements that are 
grouped into three sections:  demographic information, RWP-funded services and clinical 
information. 
 
The RSR data management process is completed within 12-18 months and includes six steps.  
Step 1 begins with raw data files.  In 2010, these files accounted for a total of 802,173 
duplicated records.  Step 2 is the first data cleaning process to remove records that should not 
have been reported (e.g., clients who did not receive an RWP-funded service or did not meet 
other parameters).  Step 3 is the de-duplication process.  This probabilistic record linking 
approach is used to identify records that are considered matches (the same client).  The 
approach was vetted and validated by an external panel. 
 
Step 4 is the merging of data into a single record after identifying clients who are matches.  Step 
5 is the second data cleaning process.  Step 6 is the development of analytic files to be used to 
conduct analysis, create reports and respond to data requests. The data management process 
results in one merged record per client.  The total number of clients receiving at least one Ryan 
White funded service is considered to be a point estimate with an upper and lower bound.  The 
upper bound requires all demographic variables that are used for matching to be the same to be 
considered the same client, while the lower bound uses the eUCI only. 
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In CY 2010, an estimated 546,156 clients received at least one Ryan White funded service.  
HRSA acknowledges several limitations of the new RSR dataset that need to be considered as 
the data are being reviewed.  The data analyses are preliminary and are not considered to be 
mature at this time.  Data quality issues, such as a high number of missing and unknown rates 
for several demographic and clinical variables, likely are impacting data.  Finally, the RSR 
dataset captures data reported by grantees, but may not fully reflect the quality of care provided 
at RWP-funded sites. 
 
Demographics 
The first data that were presented were demographics.  HRSA noted that different demographic 
reporting requirements result in different denominators for analyses.  For example, all grantees 
must report the birth year, race, ethnicity and gender of each client regardless of the services 
received.  All grantees also must report the transgender status of each client who self-identifies 
as “transgender.”  The following variables must be reported for clients who receive OAMC, 
MCM or CM services:  the first service date, enrollment status and data of death if applicable, 
poverty level, geographic unit code, HIV risk factors, HIV/AIDS status, and AIDS diagnosis.  
Housing status must be reported for clients who receive OAMC, MCM, CM or housing services.  
Medical insurance must be reported for clients who receive any core medical service or CM 
service. 
 
The preliminary 2010 RSR data are summarized and exclude missing or unknown data.  Of the 
estimated 546,156 clients who received at least one RWP-funded service in CY 2010, 68.5% of 
RWP clients were male, 30.7% were female and <1% were transgender.  By race/ethnicity, 
47.3% of RWP clients were Black non-Hispanic, 27.7% were White non-Hispanic, and 22.3% 
were Hispanic.  Women were represented at higher levels among racial/ ethnic minorities than 
men (e.g., 40% Black non-Hispanic and 28% Hispanic compared to 18% White non-Hispanic). 
 
By age, 1 in 3 RWP clients were 40-49 years of age, 24% were 50-59 years of age, 19% were 
30-39 years of age, and 9% were in the 24 and under age group.  Medicaid was the most 
frequent payer source reported (27.5%) followed by no insurance (25.5%); multiple payer 
sources can be reported with the exception of no insurance which is reported only for clients 
who were uninsured for the entire 12-month reporting period.  Some, 84.2% of RWP clients 
were stably housed.  Two-thirds of RWP clients reported an annual household income of 
<100% of the federal poverty level (FPL) and 22% reported 101%-200% of the FPL. 
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Services 
RWP Parts A, B and C grantees are required to allocate 75% of their funding to provide core 
medical services and the remaining 25% to provide support services to clients.  Providers must 
report clients who receive core medical services by number of visits and quarter with the 
exception of local Pharmacy Assistance Programs and the Health Insurance Program.  These 
programs follow support service reporting rules.  Clients are only allowed one visit/per day/per 
service.  Means and medians are shown to identify outliers in the data.  Providers must report 
clients who receive support services by quarter. 
 
For core medical services, 309,642 clients received at least one OAMC visit in 2010 and 
represented 57% of all clients who received any RWP-funded service.  These clients accounted 
for ~1.8 million visits.  The 283,876 clients who received at least one MCM visit in 2010 
accounted for ~2.9 million visits.  Oral health care (83,333 clients accounting for 291,209 visits) 
and mental health care (72,756 clients accounting for 477,347 visits) were the third and fourth 
most frequently provided services. 
 
Home health care (1,617 clients), home/community-based health care (1,698 clients) and 
hospice care (178 clients) collectively accounted for a small number of clients served, but the 
69,135 total visits are indicative of clients with more serious disease or illness.  HRSA is 
providing technical assistance to ensure that grantees report core medical services in the same 
manner. 
 
For support services, 25.4% of clients received case management services, 13.2% received 
transportation services,12.8% received health education and risk reduction services and 11.4% 
received psychosocial support services.  Eleven percent of clients received food bank/home 
delivered meals, while 9.5% received treatment adherence counseling outside of a medical or 
medical case management visit.   
 
Clinical Information 
In terms of clinical information, HRSA reviews different variables to assess the quality of care 
delivered by RWP medical care providers and calculate performance measures.  The clinical 
data represent all activities regardless of payer source; however, given high missing/unknown 
rates for many for these variables, the data reported may not fully reflect the quality of care 
provided at RWP-funded sites.  Providers reported clinical information for all clients who were 
HIV-positive and received at least one RWP-funded OAMC visit.  The total number of clients 
was 307,562 after excluding those with an HIV indeterminate status from the analysis. 
 
Some 87.8 % of clients had at least two medical care visits in 2010; 33.7% had 5-9 visits and 
13.4% had greater than 10 visits.  Of clients for whom a viral load was reported, 76.2% received 
at least 2 viral loads during the reporting period.  Missing data from the RSR dataset included 
medical care visit dates for 16,113 clients, CD4 counts for 48,658 clients and viral loads for 
57,218 clients.  HRSA will continue to provide technical assistance to grantees to improve 
reporting of these data to more accurately determine the quality of care provided to clients. 
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During the 2010 reporting period, 62% of clients received risk screening, 54% of clients received 
mental health screening, and 54% received substance abuse screening.  TB, HBV and HCV 
screening are collected in two ways in the RSR: whether the client was screened during the 
reporting period and, among clients for whom no or not medically indicated was reported, 
whether the client was screened since receiving an HIV diagnosis.  During the reporting period, 
clients received screening for TB (41%), HBV (30%) and HCV (33%); among clients for whom 
“no” or “not medically indicated” was reported for screening in CY 2010, an additional 47% were 
screened for TB, 57% for HBV and 62% for HCV.  In future report periods, HRSA intends to only 
collect if the client was ever screened since HIV diagnosis.   Nearly 80% of clients received 
highly active ART and 66% of clients were screened for syphilis at any time during the reporting 
period. 
 
HRSA’s next steps will be to conduct additional analyses with the 2010 RSR data and complete 
processing of the 2011 RSR data.  Data management processes will be refined as needed.  
Technical assistance will continue to be provided to grantees to improve the quality of data 
reported for the RSR dataset.  Best practices among grantees in reporting RSR data will be 
compiled and disseminated.  The HAB data analysis plan will be revised as needed to distribute 
multiple RSR data products in the first 3-6 months of 2013. 
 
Dr. Marrazzo moderated CHAC’s discussion with Ms. Isenberg and Ms. Malitz on the 
preliminary 2010 RSR dataset.  The discussion topics included: 
 
• HRSA’s ability to compare the RSR dataset with data from HIVQUAL and other RWP-
funded programs; 
• HRSA’s plans to address budgets of RWP-funded providers to support more complete 
entry of data into the RSR dataset; 
• HRSA’s plans to collect data on racial/ethnic groups other than NHBs, NHWs and 
Hispanics (e.g., Native Americans and Asian/Pacific Islanders) that receive RWP-funded 
services; 
• HRSA’s intention to reanalyze the RSR dataset to determine the insurance status of 
clients who receive support services; 
• the role of gender in utilization of RWP-funded services, particularly since minority 
women were represented at higher levels than men in the RSR dataset; 
• the role of treatment adherence in case management; 
• HRSA’s ability to analyze RSR data to determine the gap between the number of clients 
who received medical care and CM; 
• time and costs RWP grantees need to devote to data collection for the RSR dataset; 
• web-based access to RSR data by RWP grantees and their funded providers; and 
• the role of the RSR dataset in addressing the mandate for all HHS-funded HIV programs 
to develop core measures for the collection of uniform data on adverse outcomes. 
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CHAC congratulated HRSA on its longstanding efforts to produce the preliminary 2010 RSR 
dataset.  The members emphasized that RWP client-level data are extremely important to 
grantees in order to improve the quality of care and gain more knowledge of clients served at 
sites. 
 
CHAC’s comments and suggestions for HRSA to consider in refining the preliminary 2010 RSR 
dataset and completing analyses of the 2011 RSR data are outlined below. 
 
• HRSA should analyze the RSR data to be more granular, useful and informative in an 
ACA environment.  Additional data analysis should include the number and types of 
services utilized per client and across various age groups and specific RWP-funded 
services that will not be covered by Medicaid/Medicare.  These types of data analyses 
would be extremely helpful for program planning at the clinic level. 
• HRSA should explore methods to develop an accurate proxy measure or an appropriate 
indicator for “family health” in the RSR dataset.  In this effort, HRSA should analyze 
utilization of specific RWP-funded services (e.g., child care and pediatric development 
services). 
• HRSA should modify the data elements in future RSR datasets to specifically collect 
data on clients who self-identify as “gay” and clearly delineate and distinguish between 
“identity” and “risk behaviors.”  This information will be extremely important in guiding 
further implementation of NHAS and health disparities initiatives. 
• HRSA should attempt to limit the number of RSR data elements to those that are most 
important and easiest to extract from electronic medical records (EMRs).  This approach 
would improve the quality of data without increasing the data collection burden on RWP 
grantees. 
• HRSA should take steps to enhance the accuracy of RSR data elements related to 
adverse events or those that are ready for interventions.  For example, more emphasis 
should be directed to the HCV data elements due to important trends.  Most notably, a 
considerable proportion of the HIV-infected population has HCV.  MSM are presenting to 
STD clinics with incident HCV disease.  Treatment options for HCV are continuing to 
increase. 
• HRSA should explore the possibility of collecting data on family planning, contraception 
and other reproductive health services of RWP clients due to the large proportion of 
women at RWP-funded clinics. 
Ms. Isenberg and Ms. Malitz clarified that HRSA has completed or currently is conducting some 
of the additional analyses suggested by CHAC.  These analyses will be distributed after the 
preliminary 2010 RSR dataset is refined, finalized and cleared for release. 
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Panel Presentation: Update on the CDC and HRSA Continuum of Care Activities 
Advice Requested from CHAC by CDC and HRSA: 
• What are CHAC’s general reflections on CDC’s continuum of care data and differences 
between the CDC and HRSA surveillance systems? 
• What programmatic and evaluation strategies should CDC and its federal partners 
prioritize in terms of implementation of CAPUS? 
• What is CHAC’s guidance for CDC to respond to recommendations from the Institute of 
Medicine (IOM) Report in terms of the Medical Monitoring Project (MMP)? 
• What is CHAC’s guidance regarding HRSA’s next steps in addressing the HIV treatment 
cascade in the future? 
• What is CHAC’s guidance on improving HRSA’s data systems to collect relevant data on 
the HIV treatment cascade? 
 
Amy Lansky, PhD 
Deputy Director, Surveillance, Epidemiology and Laboratory Science/DHAP 
Centers for Disease Control and Prevention 
Dr. Lansky provided an overview of CDC’s continuum of HIV prevention and care activities in 
her portion of the panel presentation.  CDC uses the total number of HIV-infected persons in the 
United States as the denominator for all categories in the continuum of care (e.g., persons with 
HIV who are diagnosed, linked to care, retained in care, on ART and virally suppressed). 
CDC uses two data sources to calculate the continuum of care.  The National HIV Surveillance 
System (NHSS) captures data on HIV prevalence (i.e., the total number of persons infected and 
diagnosed with HIV) and persons who are linked to care.  MMP captures data on persons who 
are retained in care, prescribed ART and have viral load suppression. 
CDC collects HIV diagnosis data from 46 states and AIDS data from the District of Columbia 
and 4 other states.  These data are adjusted to account for delays in reporting new cases and 
deaths, incomplete reporting of diagnosed cases, and missing data in the HIV transmission 
category.  An extended back-calculation model is used to obtain the total prevalence in the 
United States.  In the dataset, “prevalence” is equal to the cumulative number of HIV infections 
minus the cumulative number of deaths.  “Undiagnosed prevalence” is equal to HIV prevalence 
minus the number of diagnosed HIV infections in living persons. 
The most recent linkage to care data were reported to CDC by 14 jurisdictions that submitted 
complete laboratory test results to health departments through December 2011.  CDC’s 
surveillance definition of “linkage to care” is the percentage of persons with >1 CD4 or viral load 
test results within three months of their diagnosis.  This dataset reflects persons >13 years of 
age diagnosed with HIV in 2010. 
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MMP is a complex cross-sectional survey sample that is conducted in three stages.  In stage 1, 
17 states/territories are sampled from all 50 U.S. states, the District of Columbia and Puerto 
Rico.  The sample represents 76% of all persons diagnosed with HIV in the United States.  In 
stage 2, outpatient HIV care facilities are sampled within the 17 states/territories.  In stage 3, a 
sample is taken from HIV-infected adults who received medical care in the sampled facilities in 
the time period of January-April. 
The MMP data collection process includes medical record abstraction to document clinical care, 
interviews to obtain self-reported demographic characteristics, and linkages to NHSS.  
Retention in care is determined by the number of HIV-infected adults who had at least one 
medical care visit in January-April.  Prescription of ART is determined by documentation in the 
medical record abstraction of any ART prescription in the past 12 months.  Viral suppression is 
determined by documentation in the medical record abstraction of the most recent viral load that 
is undetectable or <200 copies/mL. 
The results of CDC’s most recent continuum of care data are summarized as follows.  The HIV 
prevalence in 2009 was ~1.1 million persons.  By total population, 82% were diagnosed, 66% 
were linked to care, 37% were retained in care, 33% were prescribed ART, and 25% were 
virally suppressed.  By gender, females had slightly higher rates in most stages in the 
continuum of care compared to males, but the rate of viral suppression was basically the same 
for females (26%) and males (25%).  
By race/ethnicity, NHBs and Hispanics had lower rates in all stages in the continuum of care 
compared to NHWs.  Compared to NHWs, lower rates of NHBs were linked to care, retained in 
care, on ART and virally suppressed.  The rates of most stages in the continuum of care were 
relatively comparable between Hispanics and NHWs, but a stark difference was seen in viral 
suppression (e.g., 26% in Hispanics versus 30% in NHWs). 
By transmission category, male injection drug users (IDUs), female IDUs and MSM-IDUs 
accounted for the largest proportion of HIV diagnoses compared to MSM and heterosexual 
males and females.  Female IDUs (28%), MSM (27%) and MSM-IDUs (26%) accounted for the 
top three highest rates of viral suppression compared to the other transmission groups. 
By age, the younger age groups had lower rates of HIV diagnosis and linkages to care.  The 
rate of viral suppression was highest in the 55-64 age group (36%) and lowest in the 25-34 age 
group (15%).  Rates of HIV diagnoses and linkages to care were highest in and comparable 
among the 45-54, 55-64 and >65 age groups.  Because MMP only captures data from adults 
>18 years of age, the continuum of care data in the 13-24 age group are limited to persons who 
are diagnosed with HIV and linked to care. 
CDC acknowledges several limitations with its continuum of care data.  The dataset represents 
linkage to care data from only 14 states.  Retention in care may be underestimated because the 
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data are based on visits from January to April only.  Experiences in care most likely are different 
for persons in the younger age group of <18 years.  The samples are too small to capture data 
on racial/ethnic groups other than NHBs, NHWs and Hispanics.  Implementation of treatment 
guidelines in the future is expected to result in changes in the continuum of care. 
 
Overall, CDC’s continuum of care data showed that 75% of persons diagnosed with HIV do not 
have a suppressed viral load.  HIV diagnosis and care are critical for all age groups.  Additional 
efforts are needed to provide all PLWH with optimal HIV care, reduce disparities and ultimately 
decrease HIV transmission. 
In terms of prevention activities related to the continuum of care, CDC currently is funding the 
HIV Surveillance CoAg, Health Department HIV Prevention CoAg, and CAPUS demonstration 
project.  CDC also has drafted prevention recommendations for adults and adolescents with HIV 
in the United States, in collaboration with HRSA and other partners. 
CDC is the lead federal agency for CAPUS, but the demonstration project is being conducted in 
close collaboration with HHS and HRSA operating divisions and SAMHSA.  Of 18 jurisdictions 
that were eligible for CAPUS funding based on burden of disease, disparities and level of SDH, 
awards were made to health departments in 8 states:  Georgia, Illinois, Louisiana, Mississippi, 
Missouri, North Carolina, Tennessee and Virginia. 
CAPUS was designed to achieve two major goals.  First, the proportion of racial/ethnic 
minorities with a diagnosed HIV infection will be increased by expanding and improving testing 
capacity.  Second, linkage to and retention in care will be optimized and newly/previously 
diagnosed racial/ethnic minorities with HIV will be reengaged in prevention and care services.  
To achieve these goals, social, economic and structural barriers to HIV testing, linkage to and 
retention in care, and reengagement in prevention and care services will be addressed in 
racial/ethnic minorities. 
All 8 CAPUS grantees are required to create work plans with four mandatory components and 
allocate 25% of their funds to CBOs to support the development of human capital, partnerships, 
skills and infrastructure.  The four mandatory components of the CAPUS framework are: 
• use of surveillance data and data systems to improve care and prevention; 
• provision of HIV testing, linkage to, retention in, and reengagement in prevention, care 
and treatment; 
• provision of navigation services; and 
• strategies to address social and structural factors that directly affect HIV testing, linkage 
to, retention in, and reengagement in prevention, care and treatment. 
CAPUS grantees also are allowed to include supplemental and optional components or other 
approaches in their work plans.  The combined activities will be designed to have the greatest 
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potential to address social/structural determinants that impede the identification of unknown 
HIV-positive racial/ethnic minorities and link, retain and reengage these persons in care. 
The CAPUS project will complement CDC’s prevention portfolio by specifically focusing on the 
continuum of care and improving the health of racial/ethnic minorities living with HIV in 
disproportionately affected jurisdictions.  During the three-year demonstration project, the 8 
CAPUS grantees will identify practical and workable solutions to minimize the impact of broader 
problems on HIV testing and care.  These lessons learned will be broadly shared with other 
jurisdictions. 
CDC reviewed findings and recommendations from two recent IOM reports that focused on the 
continuum of care and will have implications for MMP.  For the first report, the IOM Committee 
was charged with (1) identifying core indicators and data elements for HIV care and supportive 
services to monitor the impact of NHAS and ACA on HIV care; (2) identifying the best sources 
of public and private data to assess core indicators; (3) identifying potential barriers to data 
collection; (4) discussing the role of HIT; and (5) addressing the analysis and dissemination of 
data. 
For the second report, the IOM Committee was charged with exploring strategies to obtain 
nationally representative estimates that will characterize and monitor the impact of ACA on 
coverage and utilization of health care among PLWH in both public and private settings.  The 
committee addressed three major questions to fulfill its charge. 
1. What approaches can be taken to collect data from a nationally representative sample of 
PLWH in the United States to establish a baseline for health insurance and healthcare 
assess prior to 2014? 
2. If obtaining a nationally representative sample is not possible, do other alternatives exist 
(e.g., using multiple existing data sources or requiring a complete accounting of all HIV-
positive persons in care) to collect data on care and utilization beyond clients enrolled in 
RWP? 
3. What strategies can be implemented to continue to regularly obtain data from a large 
nationally representative or other sample of HIV-positive persons after 2014 to monitor 
the impact of ACA on health insurance and healthcare access? 
The second report 2 contained the following recommendations that will impact MMP.   
The White House Office of National AIDS Policy (ONAP) should use multiple existing data 
sources to establish a baseline for healthcare coverage and utilization prior to 2014.  These 
data sources should include NHSS and MMP (CDC), RWP (HRSA), Medicaid/ Medicare (CMS), 
and datasets of other federal agencies, academic networks and private insurers. 
CDC should improve MMP by 2015 to ensure higher response rates and increase the ability of 
samples to be nationally representative.  ONAP and HHS should use the improved version of 
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MMP to obtain nationally representative data on the coverage and utilization of health care 
among PLWH. 
HHS should convene a multidisciplinary task force to design improvements in MMP and ensure 
that this data source remains responsive to changes in the HIV epidemic and healthcare 
environment.  ONAP and HHS should use data from Medicaid/Medicare, RWP and private 
insurers to monitor the impact of ACA on the coverage and utilization of health care at state and 
program levels. 
The IOM Committee acknowledged that three major factors will impact the implementation of 
these recommendations.  First, eligibility of healthcare coverage and access to care will vary 
among states because ACA provisions will not be uniformly implemented by all states.  Second, 
MMP cannot be used for state-level analyses because persons in every state are not included in 
this nationally representative sample.  Third, data from Medicaid/Medicare, RWP and private 
insurers will provide information on the effect of ACA at state and program levels, but not at the 
national level. 
Overall, CDC’s continuum of care data showed that an overwhelming 75% of ~1.1 million PLWH 
in the United States do not have a suppressed viral load.  CDC is continuing to target its HIV 
prevention activities to testing and linkage to care, retention in care, treatment adherence, and 
enhanced use of surveillance data to measure progress along the continuum of care.  However, 
significant disparities in HIV by race/ethnicity and age persist.  CDC’s next steps will be to 
respond to the IOM recommendation of using MMP to obtain national estimates to monitor the 
NHAS goal of improving health outcomes of PLWH. 
Rupali Doshi, MD, MS 
Medical Officer, Office of the Associate Administrator/HAB 
Health Resources and Services Administration 
Laura Cheever, MD, MS 
Deputy Associate Administrator, HIV/AIDS Bureau 
Health Resources and Services Administration 
Drs. Doshi and Cheever provided an overview of HRSA’s activities to address the HIV care 
continuum in their portion of the panel presentation.  The 2007 Cheever publication, HRSA 
Continuum of Engagement in HIV Care, has been an instrumental resource for RWP clinics to 
focus on the full spectrum of PLWH, including persons who are not engaged, intermittently 
engaged or fully engaged in HIV primary medical care.  The 2011 Mugavero, et al. framework 
provided additional guidance to enhance understanding of healthcare service delivery for 
PLWH. 
HRSA’s direct funding to RWP Parts A, B, C, D and F grantees addresses all areas of the HIV 
care and treatment continuum.  HRSA also is continuing to fund SPNS Initiatives and research-
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oriented demonstration projects to fill gaps in knowledge, identify cost-effective evidence-based 
interventions, and compile best practices in this area. 
 
HRSA will award $1 million annually over the project period of the “System Linkages” SPNS 
Initiative for state-level grantees to improve HIV diagnosis and linkage to care.  Grantees will 
take a public health approach in this effort by using their surveillance data to engage diverse 
partners in identifying and linking persons to HIV to care.  Most notably, grantees will implement 
a quality improvement “plan/do/study/act” model for rapid dissemination and testing of promising 
practices across the network. 
 
HRSA’s SPNS Initiative for correctional settings was successful in reaching stationary PLWH in 
state prisons, but the ability to reach PLWH in local/county jails has been much more difficult 
due to the transient nature of this population.  As a result, HRSA closely collaborated with CDC 
to develop a SPNS Initiative for HIV testing and reengagement of HIV-positive persons in care 
specifically for jail settings. 
HRSA is funding a SPNS Initiative focusing on various uses of data to improve care for HIV 
patients.  For example, the Louisiana grantee has been successful in engaging all parts of the 
hospital system in the state to flag and report data on PLWH who need to be reengaged in care.  
HRSA is allocating MAI funds from the HHS Secretary to replicate the Louisiana model in other 
jurisdictions.  HRSA is funding an initiative to determine whether opiate replacement therapy 
can help PLWH to stabilize their lives and engage in care through primary care settings. 
Despite these initiatives, HRSA recognizes that more data are needed to effectively reach 
special populations with a disproportionate impact of HIV and improve their quality of care.  For 
young MSM of color, for example, HRSA is partnering with the Adolescent Treatment Network 
(ATN) to rapidly distribute their best practices to RWP grantees and provide ATN with access to 
RWP clients. 
Quality management is a key component of the RWP legislation that addresses all aspects of 
the care continuum.  Most notably, HRSA awarded a five-year cooperative agreement to the 
New York State AIDS Institute to provide quality management training and technical assistance 
to RWP grantees through NQC.  This initiative focuses on retention in care through the In+Care 
Campaign and has engaged >500 providers who deliver care to >400,000 patients.  The 
cooperative agreement represents a successful collaborative model among HRSA, NQC and 
providers in identifying best practices of retention in care and testing new quality measures. 
The HHS Secretary recently publicized 7 measures for HHS-funded HIV activities that should be 
aligned and coordinated among federal agencies.  These measures are consistent with the 
NHAS and National Quality Strategy goals.  At this time, NQF is considering whether to endorse 
4 of HRSA’s 7 proposed measures.  HRSA also is collaborating with CMS on implementation of 
the measures in EMRs through the Meaningful Use Program.  
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HRSA is continuing to conduct activities to address its mandate to develop quality measures.  
Several of HRSA’s performance measures directly focus on the HIV care continuum.  Most 
notably, efforts are underway at HRSA and CDC to obtain national endorsement from NQF on a 
number of HIV care measures, including indicators for retention in care, ART and viral load 
suppression. 
 
HRSA has analyzed RWP data to better understand the continuum of care.  HRSA’s sources for 
primary and secondary client-level data and aggregate data include the RSR dataset, ADAP 
report, HAB performance measures, and In+Care Campaign database.  RSR data showed that 
546,156 clients received RWP-funded services in 2010.  HRSA’s denominator in these analyses 
was based on CDC’s estimate of 940,000 persons with a known HIV-positive diagnosis in the 
United States at the end of 2009.  Of these persons, ~58% received an RWP-funded service in 
2010.  However, the numerator includes persons with an unknown HIV status and persons who 
might be HIV-negative, but are eligible for RWP-funded services. 
The RSR dataset only captures the HIV status of clients who received OAMC, MCM and CM 
services.  The number of HIV-positive clients who had a medical care visit or CM visit was 
429,000.  This figure accounted for 79% of clients who accessed RWP-funded services in 2010.  
The number of clients who had at least one medical care visit was ~307,000.  This figure 
accounted for 72% of clients who were known to be HIV-positive.  “Retention in care” was 
defined by the HAB performance measure of clients who had two visits separated by at least 90 
days.  The percentage of HIV-positive RWP clients who were retained in care was 72%.  The 
remaining 28% of clients had at least one medical care visit, but were not retained in care. 
Of uninsured HIV-positive RWP clients, 85,000 (or 83%) had at least one medical care visit and 
17% had no medical care visits.  The number of RWP clients who had at least one visit and 
received an ART prescription at any point during the reporting period was 208,000 (or 68%).  
The number of RWP clients with viral load suppression who had at least one medical care visit 
was 174,000 (or 57%).  The number of RWP clients who received ART and had viral load 
suppression was 145,000 (or 69%).  In the larger population of HIV-positive RWP clients who 
had a medical care or CM visit, 41% had an undetectable viral load. 
Ms. Dempsey moderated CHAC’s discussion with Drs. Lansky, Cheever and Doshi on the CDC 
and HRSA continuum of care activities.  The discussion topics included: 
• potential errors or underestimates in the CDC and HRSA datasets on the percentage of 
persons in care due to the migration of patients from RWP clinics to private practices or 
care systems in other states; 
• geographic variations in the treatment cascade and the impact on population health in 
states with the best treatment cascade; and 
• persistent problems in the treatment cascade with specific subgroups, particularly 
ongoing increases in HIV among gay/bisexual men and minorities. 
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CHAC made several comments and suggestions for CDC and HRSA to consider in enhancing 
their continuum of care datasets. 
 
• Most of the continuum of care projects focus on HIV testing and linkage to care, but 
additional resources should be allocated to retention in care to dramatically improve 
outcomes. 
• CDC and HRSA should make efforts to collect continuum of care data by region to better 
understand geographic differences in the treatment cascade and more effectively target 
interventions. 
• CDC and HRSA should place stronger emphasis on targeting prevention services to 
HIV-uninfected persons. 
• HRSA should conduct intensive case management to determine reasons for diagnosing 
HIV cases with CD4 counts <50 copies/mL.  The diagnosis of HIV-infected persons with 
CD4 counts <200 copies/mL should be viewed as a sentinel event.  A major goal of 
RWP clinics should be to increase the CD4 counts at which persons are diagnosed with 
HIV. 
• The IOM committee recommended that HHS convene a multidisciplinary task force to 
design improvements in MMP.  The HHS Office of HIV/AIDS and Infectious Disease 
Policy is developing indicators across the HIV system at this time and should be 
extensively engaged in the task force. 
• CDC and HRSA should explore the possibility of releasing a joint FOA for the 
development of a new and innovative treatment cascade to achieve a greater impact on 
retaining hard-to-reach populations in care (e.g., African American MSM).  The treatment 
cascade should be designed with multiple medical services and social services that are 
attractive to and needed by these subgroups, including job training and education.  
Grantees of the joint CDC/HRSA FOA could pilot the innovative treatment cascade in 
select communities across the country. 
• CDC and HRSA should track the actual experiences of PLWH, particularly their barriers 
to care (e.g., income, transportation needs, employment status, availability of health care 
and psychological issues).  This type of information would help to enrich the CDC and 
HRSA continuum of care datasets. 
• CDC and HRSA should place more emphasis on providing education and accurate 
information to PLWH regarding the benefits of remaining in care.  PLWH often are 
informed of the negative aspects of care and are fearful of remaining in care. 
Panel Presentation: Update on National Viral Hepatitis Activities
Ronald Valdiserri, MD, MPH 
Deputy Assistant Secretary for Health, Infectious Diseases Director 
Office of HIV/AIDS and Infectious Disease Policy 
U.S. Department of Health and Human Services 
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Advice Requested from CHAC by HRSA: 
• How should HRSA and CDC coordinate messaging for HIV and HCV testing in light of the 
USPSTF draft guidelines? 
• What is CHAC’s guidance regarding ideal audiences and modes of dissemination of the 
SPNS findings? 
• What are CHAC’s suggestions regarding sustainability of telemedicine systems for 
ongoing technical assistance and clinical capacity building in RWP-funded clinics? 
• What is CHAC’s feedback on the applicability of clinic delivery models in an HCV mono-
infected population?
 
 
Dr. Valdiserri covered the VHAP implementation plan in his portion of the panel presentation.  
IOM issued the 2010 Hepatitis and Liver Cancer report that characterized viral hepatitis (VH) as 
a “silent epidemic” in the United States.  The report further concluded that healthcare providers, 
patients and consumers have limited knowledge of VH, its diagnosis and available treatment 
options.  In response to the IOM report, Dr. Howard Koh, the HHS Assistant Secretary for 
Health, convened an interagency workgroup to develop VHAP as the first comprehensive 
strategic VH action plan for the nation. 
 
The HHS workgroup compiled key findings of the IOM report to outline specific action steps and 
recommendations for VHAP based on six priority areas: 
 
• educate providers and communities to reduce health disparities in VH; 
• improve VH testing, care and treatment to prevent liver disease and cancer; 
• strengthen surveillance to detect VH transmission and disease; 
• eliminate transmission of vaccine-preventable VH; 
• reduce VH cases caused by drug-use behaviors; and 
• protect patients and workers from healthcare-associated VH. 
 
The HHS workgroup proposed four major VHAP goals to specifically focus on the U.S. 
population of ~3-5 million persons with chronic HBV and/or HCV infection.  By 2020, increase 
the proportion of persons who are aware of their HBV infection from 33% to 66%.  By 2020, 
increase the proportion of persons who are aware of their HCV infection from 45% to 66%.  By 
2020, reduce the number of new HCV infections by 25%.  By 2020, eliminate mother-to-child 
HBV transmission. 
 
HHS’s position is that the VHAP goals are achievable with full implementation and meaningful 
support at the national level, but new funding was not allocated for program activities.  However, 
HHS is leveraging existing resources across its federal agencies to the extent possible to 
achieve the VHAP goals. 
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VHAP has led to several important changes to date.  Most notably, the national conversation 
and profile of VH were raised to educate providers, consumers and the private sector about the 
magnitude and scope of this epidemic in the United States.  Clear priorities were established 
and a strong rationale was provided to improve and stimulate cross-agency coordination and 
collaboration.  A measure of accountability was provided and opportunities were identified to 
highlight unmet needs in VH. 
 
Following the release of VHAP, Dr. Koh directed the HHS agencies and relevant offices to 
designate subject-matter experts to serve on the Viral Hepatitis Implementation Group (VHIG).  
However, federal partners and entities outside of HHS also are represented on VHIG:  Federal 
Bureau of Prisons, Department of Veterans Affairs (VA), and White House Initiative on Asian 
Americans and Pacific Islanders.  The overarching role of VHIG is to identify opportunities to 
leverage existing resources, establish priorities and advance policy.   
HHS awarded a contract to Battelle to evaluate the impact of VHAP to date at state, local and 
community levels.  At the federal level, several of the 142 VHAP action steps for 2011-2012 
have been completed or are underway in the six priority areas, but some initiatives have not 
been initiated due to the lack of resources.  Key examples of coordination across the HHS 
agencies are highlighted below. 
An inventory was created with both federal and non-federal educational materials to maintain 
and distribute VH information from multiple sources through the CDC National Prevention 
Information Network.  For Hepatitis Awareness Month in May, 10 blogs were hosted; the VH risk 
assessment tool was launched; the first “National Viral Hepatitis Testing Day” was held on May 
19, 2012; and FDA issued safety guidance on blunt-tip suture needles. 
USPSTF issued draft HCV testing guidelines with a deadline of December 24, 2012 to submit 
public comments.  Because VHAP calls for the alignment of HCV screening guidelines to the 
degree possible, VHIG is continuing to explore strategies to address differences between 
USPSTF’s draft guidelines and CDC’s final recommendations on HCV testing to minimize 
confusion in the field.  VHIG is aware that data will be needed from multiple sources (e.g., 
CHAC, academic researchers, community advocates and CBOs) to inform this effort.  Steps 
have been taken to achieve the VHAP goal of eliminating mother-to-child HBV transmission. 
Articles recently were published in the MMWR and the American Journal of Public Health 
discussing the reemergence of new HCV infections among younger IDUs that is linked to the 
epidemic of prescription opioid use in the United States.  To increase recognition of this issue, 
HHS hosted a meeting in the summer of 2012 for CDC to make presentations to researchers in 
the National Institute on Drug Abuse. 
HHS will compile key outcomes from the meeting to convene a cross-agency, cross-disciplinary 
and multi-sectoral technical consultation in Washington, DC in the first quarter of 2013.  Federal 
agency representatives, researchers, state/local health departments and community advocates 
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will be invited to the consultation to describe the current epidemiology of HCV among IDUs; 
characterize younger IDUs who are at increased risk for HCV; explore prevention strategies that 
can be implemented; and highlight critical gaps in epidemiology data, surveillance data and 
prevention research. 
The key challenges and opportunities for VH in FY2013 and beyond include the need to prepare 
providers to take advantage of the rapidly evolving science base of new HCV therapies and 
increase health literacy among persons with chronic HCV.  Gaps in funding need to be filled to 
expand, share and improve VH surveillance data for both public health and clinical settings and 
establish a baseline.  ACA might provide opportunities for improved diagnosis, prevention and 
treatment of HBV and HCV. 
Because the existing VHAP action steps are intended to be completed in 2013, additional VH 
efforts will need to be identified beyond 2013.  Full implementation of VHAP will be limited if 
reliance is solely placed on the ability of federal agencies to leverage resources.  Overall, VHAP 
has been an extremely positive initiative to date due to close coordination and collaboration 
among the federal partners.  VHAP is available on both the CDC.gov and AIDS.gov websites.  
The VHAP Year 1 Interagency Implementation Progress Report was distributed to CHAC in the 
meeting packets. 
Seiji Hayashi, MD, MPH, FAAFP 
Chief Medical Officer, Bureau of Primary Health Care 
Health Resources and Services Administration 
Dr. Hayashi covered ongoing activities by the Bureau of Primary Health Care (BPHC) in his 
portion of the panel presentation.  The mission of BPHC is to improve the health of the nation’s 
underserved communities and vulnerable populations by assuring access to comprehensive, 
culturally-competent and quality primary healthcare services. 
Of 20.2 million patients served by HRSA funded health centers in CY2011, 93% were below 
200% of the FPL, 62% were racial/ethnic minorities, 36% were uninsured, ~1 million were 
homeless, 863,000 were migrants or seasonal farmworkers, and 188,000 were residents of 
public housing.  FQHCs represent 1,128 grantees at >8,500 service sites.  The health center 
workforce of >138,000 staff includes 9,937 physicians and 6,934 nurse practitioners, physician 
assistants and certified nurse-midwives. 
The HRSA Uniform Data System (UDS) showed that HIV testing in health centers increased 
from 691,208 persons in 2009 to 883,548 persons in 2011.  However, the number of HIV 
patients and HIV care visits has remained relatively stable over this time.  FQHCs provide care 
to only 0.5% of the HIV-positive patient population.  Moreover, the 12 Cities in the “Enhanced 
Comprehensive HIV Prevention Planning and Implementation for Metropolitan Statistical Areas 
Most Affected by HIV/AIDS” (ECHPP) Program account for 40%-50% of all HIV testing 
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performed by FQHCs.  BPHC is aware of the need to promote more testing in rural or less 
populated areas. 
HBV testing in FQHCs decreased from 256,133 persons in 2010 to 228,050 persons in 2011.  
The number of HBV patients and HBV care visits also decreased over this time.  HCV testing in 
FQHCs increased from 162,320 persons in 2010 to 197,987 persons in 2011.  An increase was 
seen in the number of HCV patients, while a decrease was observed in the number of HCV care 
visits over this time. 
BPHC informally asked ~30-40 health centers and networks on their HIV testing.  The data 
showed that on average, health centers provided HIV testing at least once to ~15% of all 
patients 13-64 years of age and HCV testing to ~15% of all patients in the 1945-1965 birth 
cohort.  However, these data were extracted from EMRs and were available for the past few 
years only, and therefore, the numbers would be grossly under-reported. 
BPHC created a quality strategy with three overarching aims of better care, improved population 
health and affordable care.  Emphasis will be placed on four key action steps and milestones to 
achieve these goals.  “Access” to testing and care will require partnerships with existing 
community infrastructures and organizations and utilization of electronic platforms, tele-health 
and other technologies.  “Comprehensive services” beyond testing will need to be provided. 
“Integrated care” (e.g., enabling services, primary care, HIV/STD/VH services, and sexual 
health/reproductive health services) will need to be packaged in a coherent, simplified and 
streamlined manner to improve the ability of PCPs to more efficiently and effectively deliver care 
to patients.  An “integrated health system” will need to be established with FQHCs playing an 
integral role along with hospitals, specialists and diagnostic services. 
Over the past year, BPHC has conducted a number of activities and offered several incentives 
in five major categories to assist FQHCs in responding to the overarching aims, key action steps 
and milestones of the quality strategy.  For “policies and programs,” BPHC engaged Primary 
Care Associations (PCAs) to disseminate CDC’s testing and treatment guidelines.  
For “funding,” BPHC awarded a $10 million supplement to dually-funded RWP grantees and 
health centers to increase delivery of care.  A $44 million supplement was awarded to support a 
PCMH initiative with a strong and explicit focus on HIV/AIDS.  Funding was allocated to support 
the Community Health Applied Research Network that includes an HIV/AIDS research node.  
The Center for Integrated Health Solutions was funded in partnership with SAMHSA to integrate 
primary care and behavioral health services with specific activities on HIV/AIDS and VH.  A $20 
million award will be made to 30 Health Center Control Network Program grantees in the near 
future 
For “technical assistance,” BPHC formed an internal partnership with HAB to provide guidance 
to health centers on the tele-health initiative.  Additional technical assistance was provided to 
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FQHCs through collaborations with SAMHSA and national organizations (e.g., National Health 
Care for the Homeless Council, National Association of Community Health Centers (NACHC), 
Fenway Institute, and Association of Asian Pacific Community Health Organizations).  Some of 
these initiatives will focus on HIV and HBV, including perinatal transmission of HBV. 
 
For “data collection and dissemination,” BPHC intends to adopt HIV positivity and linkage to 
care as new UDS measures that will be reported by all HRSA funded health centers.  A survey 
will be administered to obtain information on 4,000-5,000 FQHC patients.  The survey will 
include questions on HBV and HCV testing.  For “partnerships and collaborations,” BPHC has 
enhanced its relationships with internal bureaus, federal partners and national organizations 
(e.g., HAB, CDC, NACHC, PACs and the National Alliance of State and Territorial AIDS 
Directors (NASTAD)). 
 
Health centers have made tremendous progress to date on addressing the priorities of the 
BPHC quality strategy.  BPHC will continue to focus on the implementation of quality 
assurance/quality improvement (QA/QI) systems, adoption of EMRs for the Meaningful Use 
Program, PCMH recognition, improvement in clinical outcomes, and development of team-
based care. 
 
Despite this progress, health centers continue to be challenged by several issues.  In terms of 
national guidelines, discrepancies between the CDC and USPSTF HCV testing 
recommendations are causing uncertainty and confusion at the clinic level.  In terms of HIT and 
data collection issues, not all FQHCs have EMRs in each clinic that are used by each provider 
at this time.  In terms of workforce shortages, the limited number of PCPs and HIV/AIDS 
specialists hinders the ability of FQHCs to recruit new staff.  In terms of financial constraints, 
FQHCs have insufficient resources to meet the diverse needs of their patients. 
 
Todd Wills, MD 
Associate Professor of Internal Medicine & Fellowship Program Director 
Division of Infectious Disease and International Medicine 
University of South Florida, Morsani College of Medicine 
 
Dr. Wills covered the SPNS HCV Treatment Expansion Initiative in his portion of the panel 
presentation.  Over the 2010-2014 project period, 29 demonstration sites in RWP-funded HIV 
clinics will implement an HCV treatment program with annual funding of $80,000 for two project 
years.  The grantees will use their awards to implement and expand identification and treatment 
of HCV patients within their comprehensive HIV clinics. 
 
The project was designed with an initial 15-clinic cohort in years 1-2 (September 2010-August 
2012) and a second 14-clinic cohort in years 2-3 (September 2011-August 2013).  Analysis and 
data dissemination will be conducted in 2014.  Many of the demonstration sites are located in 
urban settings with the highest prevalence of HCV, but efforts are underway to implement the 
project in rural settings as well. 
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HRSA funded the project based on several factors.  Most RWP-funded clinics have extensive 
experience with an array of complex social and medical issues that are common to both HIV 
and HCV.  Most RWP clinics have programs or access to programs for substance abuse 
counseling and treatment.  To establish a model care system for managing HCV in co-infected 
persons, emphasis on substance abuse will play a critical role.  Primary care relationships and 
services provided in RWP-funded clinics provide an optimal environment to integrate HCV 
management. 
 
In designing the project, HRSA and the grantees identified numerous elements at both provider 
and patient levels that would predict a successful HIV/HCV program: 
 
• a medical director dedicated to treating HCV patients; 
• an overarching goal to address an unmet need in the treatment of patients; 
• a key medical provider with responsibility for treating and monitoring HCV patients; 
• ongoing evaluation of candidates for HCV treatment; 
• a system to identify all persons with HCV co-infection; 
• rigorous treatment protocols; 
• client support groups; 
• patient education; 
• access to psychiatry and mental health services; 
• access to chemical drug dependency counseling and treatment; 
• medication access and payment coverage; 
• availability of in-clinic interferon injections; and 
• access to liver biopsies. 
The next step for HRSA and the grantees was to examine three potential models of care 
delivery to implement the project.  Model 1 is primary care delivery with expert backup.  This 
collaborative management model involves a primary care HIV provider with no/limited expertise 
in HCV and a specialist with expertise in HCV management.  The specialist would perform the 
initial patient evaluation, approve treatment initiation and decide on the specific regimen for the 
patient.  The PCP would monitor the patient for treatment response and adverse effects.  Clinics 
that do not have a formal HCV treatment program and have a relatively low volume of patients 
who receive HCV therapy typically would implement model 1. 
Model 2 is integrated care without a designated HCV clinic.  This model typically involves an 
established HCV treatment program and a formal HCV co-infection treatment program.  The 
medical provider and team at the HIV clinic would be responsible for initially evaluating the 
patient, initiating treatment if indicated, evaluating the patient’s response to therapy, and 
monitoring the patient for adverse reactions.  An expert would be consulted only if the patient 
presented with major complications related to underlying liver disease. 
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Model 3 is integrated care with a designated HCV clinic.  This model involves a team of 
providers with experience, interest and training in the management of HCV co-infected persons.  
The co-infection clinic would be held in the comprehensive HIV care clinic at a designated time.  
A nurse, nurse practitioner, pharmacist or other team member with frequent interaction with a 
physician typically would be responsible for monitoring the treatment of patients. 
The grantees recently completed year 2 of the project and identified several major barriers to 
implementation.  At the patient level, personal experiences of the patient or anecdotal 
experiences of other patients either helped or hindered the clinic’s ability to link patients to HCV 
treatment.  Unstable housing, employment status and social issues also significantly affected 
implementation of the project.  To address these barriers, some grantees provided HCV 
treatment in a “Healthcare for the Homeless” model.  Other patient barriers included adherence 
requirements, the distance to clinics and transportation needs. 
At the provider level, barriers to implementation included lack of training and experience; staff 
turnover; and expectations of adverse events, time or resource demands of the clinic, and better 
treatment options in the future.  At the system level, benefits for patients from ADAP, Medicaid 
and private insurance have been inconsistent across states.  Support from specialty services 
(e.g., gastroenterology, psychiatry, mental health and substance abuse services) has been 
insufficient and unreliable.  The ability of clinics to coordinate services across multiple agencies 
has been difficult. 
Despite these challenges, the grantees have achieved early successes in the project.  Several 
clinics serve as medical homes and are able to provide supportive resources to patients who 
are on HCV treatment (e.g., optimal nutrition, support groups and familiar nurses).  Patients who 
have completed HCV treatment serve as peer counselors for patients who are initiating therapy.  
Some clinic staff members serve as dedicated “patient trackers” to ensure patients present for 
their appointments and laboratory tests.  Clinic-based injections have been beneficial for 
patients, particularly for those with an IDU history. 
The tele-medicine teacher/learner/treater community model has been extremely successful in 
decreasing fear among providers with various levels of expertise in initiating HCV treatment.  
Monthly video conference calls are held for clinic staff to share lessons learned, best practices 
and preliminary successes in HCV treatment on an ongoing basis.  The iterative learning model 
played a significant role in dramatically increasing the number of patients who were enrolled in 
HCV treatment from ~50-60 patients in year 1 of the project to 250 patients in year 2. 
Dr. Marrazzo moderated CHAC’s discussion with Drs. Valdiserri, Hayashi and Wills on the 
national VH activities that are underway.  The discussion topics included: 
• efforts by the SPNS HCV Treatment grantees in enrolling patients with active alcohol/ 
substance abuse behavior; and 
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• potential incentives to increase participation by gastroenterologists in HCV treatment of 
patients. 
CHAC made several comments and suggestions for the federal agencies to consider in further 
implementation of national VH activities. 
• The federal agencies should formalize plans at this time to provide necessary training 
and skills to the healthcare workforce to cure the serious infection of VH in the large U.S. 
population of ~3-5 million persons.  For example, the agencies should fund initiatives to 
build on and scale up successes of the AIDS Education Training Center (AETC) model 
and other innovative programs to increase engagement and capacity of PCPs across the 
healthcare workforce in VH treatment. 
• The grantees of the SPNS HCV Treatment Expansion Initiative should review important 
lessons learned from the VA care delivery model.  The VA currently delivers care to 
>120,000 veterans with chronic HCV infection using a team approach that includes mid-
level providers.  The VA model could assist the grantees in addressing barriers at both 
provider and system levels. 
• Substance abuse care and treatment should be characterized as a mandatory element 
or one of the most critical components in developing expert models of care for HCV.  
Substance abuse serves as the major barrier to patients engaging in and adhering to 
HCV treatment until cured.  Moreover, many providers exclude patients with active 
substance abuse behavior from HCV treatment. 
• Consumer education should be considered at the same level of importance as provider 
education to achieve system-level changes in VH.  Knowledge and understanding of the 
benefits of diagnosis, care and treatment are extremely limited in the large U.S. 
population of ~3-5 million persons with chronic HBV and/or HCV infection.  
Dr. John Ward, Director of DVH, announced some upcoming events in follow-up to CHAC’s 
suggestions on increasing knowledge of VH throughout the healthcare workforce.  CDC will 
convene a stakeholder panel on January 11, 2013 with professional medical associations and 
mid-level providers to increase awareness of VH and identify collaborative opportunities to 
utilize educational channels for dissemination of quality VH information. 
CDC intends to convene a follow-up stakeholder panel with HRSA, industry partners and 
continuing education providers to specifically focus on education of the workforce.  CDC is 
continuing to consult with professional education programs of its industry partners to assist in 
these efforts. 
Overview of Promising Practices in PEPFAR
Philippe Chiliade, MD, MHA 
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Medical Officer, Division of Training and Capacity Development/HAB 
Health Resources and Services Administration 
Advice Requested from CHAC by HRSA: 
• What is CHAC’s feedback on HRSA’s proposed approach to identify a few innovations 
and best practices from PEPFAR that could be adapted, piloted and rapidly implemented 
into the U.S. HIV program? 
Dr. Chiliade presented an overview of PEPFAR promising practices and innovations that 
potentially could be applied to domestic HIV/AIDS programs and describe a framework to 
translate selected best practices to the domestic HIV response.  In 2003, PEPFAR was 
launched to provide emergency access to ART to millions of persons in resource-limited 
settings.  With its reauthorization in 2009, PEPFAR increased its focus on sustainability, country 
ownership and scale-up of ART to >6 million of persons.  In recent years, the demand increased 
for dissemination of PEPFAR innovations, promising practices and lessons learned. 
HAB conducted a peer-reviewed literature of published PEPFAR and other global HIV services.  
HAB used a combination of peer review search methods and non-traditional search techniques 
to extract PEPFAR gray papers and identify best practices.  Most of PEPFAR/Global 
innovations and promising practices are not published in peer-reviewed journals, but through 
gray papers, conference abstracts, social media and networks.  U.S. government agencies, 
universities and organizations are expected to expand the peer-reviewed literature on PEPFAR 
over the next few years.  Moreover, emerging publications are expected to analyze, test or 
systematically review some evidence-based data on PEPFAR innovations. 
HAB conducted a literature review with an overarching goal of identifying PEPFAR promising 
practices that have the potential to help close gaps in the continuum of domestic HIV/AIDS care 
and focus on care and treatment.  Continuum of care data show that of HIV-positive persons, 
around 20% are unaware of their infection, 62% are linked to care, 41% are retained in care, 
36% are prescribed ART, and <28% are virally suppressed.   
The literature review resulted in HAB organizing PEPFAR promising practices and innovations 
into six major categories and three classes.  The “task-shifting” category is for PEPAR practices/ 
innovations that redefine roles in order for other types of practitioners to provide HIV/AIDS care 
and treatment to patients.  Examples include shifting tasks from physicians to nurses (e.g., 
monitoring and dispensing medications to stable patients); from nurses to skilled practitioners 
(e.g., providing basic care and treatment, testing and counseling); and from skilled practitioners 
to lay workers (e.g., providing testing, counseling and education). 
The “peer-based solution” category is for PEPAR practices/innovations that use workers or 
support systems with the same experiences of a target group.  Local residents, PLWH, or 
persons of the same origin, gender, religion, sexual orientation or workgroup as the HIV/AIDS 
patient can be trained to facilitate treatment adherence, encourage retention in care, and 
  
 
DRAFT Meeting Minutes: CDC/HRSA Advisory Committee on 
HIV, Viral Hepatitis and STD Prevention and Treatment 
December 11-12, 2012  ║ Page 40 
overcome personal barriers to social/structural determinants.  Examples of peers include sex 
workers, MSM, HIV-positive mothers and prisoners. 
The “community support” category is for PEPAR practices/innovations that strengthen the 
investment and interaction of the community and fully utilize community resources.  Examples of 
community support include involvement of the community in the care and education of orphaned 
children with HIV; engagement of celebrities or well-known/well-regarded community actors; 
and integration of local government into the HIV/AIDS response.  Many aspects of the 
community support category overlap with those in the peer-based solution category. 
The “location” category is for PEPAR practices/innovations that specifically focus on physical 
and temporal aspects to address barriers to HIV care, including access, stigma and knowledge.  
Examples of location-based activities include the placement of HIV services inside integrated 
care centers to improve privacy and reduce stigma; creation of mobile centers for hard-to-reach 
areas; increased access to HIV care for stigmatized populations to present to clinics during 
night or weekend hours of operation; and home visits. 
The “communication” category is for PEPAR practices/innovations that improve communication 
between a variety of stakeholders, including patients-medical providers, service providers-
communities, communities-PLWH, and families-PLWH.  Examples of communication include 
technology to facilitate service delivery (e.g., short messaging services (SMS) to remind patients 
of appointments and drug regimens or to transmit laboratory results to facilities) and programs 
that empower serodiscordant couples to openly discuss their HIV status to prevent transmission 
of infection. 
The “policy” category is for PEPAR practices/innovations that guide the implementation of care 
and treatment practices at the structural level.  Examples of policies include dissemination and 
determination of the type, regimen and characterization of drugs; harm reduction policies rather 
than criminalization of high-risk groups; and changes in training curricula and the scope of 
practice to allow for task shifting among healthcare workers. 
The six major categories of PEPFAR innovations fall into the programmatic and technological 
classes, but a third class is solely devoted to technology.  Examples of technology include SMS, 
physical hardware, mobile diagnostics, point-of-care testing, and crowd sourcing/crowd 
mapping.  The technology class can span the entire gradient of classes or serve as a 
standalone category. 
PEPFAR and the broader global HIV/AIDS response have produced a number of innovations 
and promising practices.  Efforts should be made at this time to gather, analyze and prioritize 
practices that have the most promise for successful application and translation to domestic HIV/ 
AIDS programs.  However, the most significant and relevant domestic needs should be first 
evaluated to narrow the search and focus the identification and translation of global best 
practices.  Both domestic and international HIV/AIDS experts should be engaged to identify 
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priority initiatives.  The SPNS Program or other existing infrastructures should be utilized to 
adapt, pilot and monitor the quality and outcomes of PEPFAR promising practices in U.S.-based 
settings prior to scale-up. 
CHAC supported HRSA’s proposed approach of organizing PEPFAR promising practices and 
innovations for translation to U.S. HIV/AIDS programs, selecting those more likely to have a 
cost-effective impact on the domestic continuum of response, adapting a few selected, one for 
pilot and if successful for scale up.  The members made several comments and suggestions for 
HRSA to consider in its next steps to advance this initiative. 
• HRSA should explore the possibility of encouraging RWP grantees to replicate country 
operating plans in which countries are directed to scale-up treatment based on the local 
epidemic and treatment coverage of the community.  For the U.S. model, RWP grantees 
should aim to achieve population-level impact through solid public health and clinical 
outcomes in jurisdictions with the highest prevalence of HIV/AIDS. 
• PEPFAR’s global successes in linkage to and retention in care, viral suppression, and 
task shifting for both prevention and treatment/care should be prioritized and piloted as 
the first three initiatives in the international-to-domestic translation of HIV/AIDS activities.  
However, the input and expertise of PLWH should be key components in all phases of 
identifying, adapting, piloting and broadly implementing PEPFAR promising practices in 
domestic settings. 
• Community health workers/promotores increasingly are being integrated into the U.S. 
healthcare system with more training, research and medical assistance.  These workers, 
particularly those who are HIV-positive or HIV-affected, should be an integral part of the 
task-shifting category to reach underserved or linguistically-isolated populations. 
• Emphasis should be placed on PEPFAR and other international models that allow 
patients to access HIV/AIDS care in an easier and more convenient manner outside of 
provider practices.  For example, task shifting could include pharmacists who manage 
patients via telephone calls or online follow-up.  The Vancouver, Canada model involves 
the submission of HIV/AIDS test results to a centralized source and a standardized 
protocol to address treatment failure.  Other models have been tremendously successful 
in reaching PLWH and engaging their friends and families for support to assure retention 
in care. 
 
 
Antigone Dempsey MEd, CHAC co-Chair 
Deputy Director, Knowledge, Transfer and Technical Assistance 
HIV/AIDS Lead, Altarum Institute 
Preparation for the CHAC Business Session
  
 
DRAFT Meeting Minutes: CDC/HRSA Advisory Committee on 
HIV, Viral Hepatitis and STD Prevention and Treatment 
December 11-12, 2012  ║ Page 42 
Ms. Dempsey announced that the business session would include CHAC’s formal votes on draft 
recommendations proposed by the Sexual Health Workgroup, Viral Hepatitis Workgroup, and 
PACHA/CHAC Disclosure Workgroup.  CHAC’s discussion of other items that also would need 
to be addressed during the business session resulted in the members suggesting ~9 topics.  To 
make the business session as productive and efficient as possible, CHAC agreed to group 
these issues into four major categories. 
Category 1:  Impact of ACA on RWP and PLWHA 
Champions:  Dr. Kathleen Clanon; Mr. Ernest Hopkins 
Category 2:  Data issues 
Champion:  Dr. Carlos del Rio; Dr. Jennifer Kates 
• Treatment cascade 
• Linkage to and retention in care 
• Late diagnosis of HIV 
• Additional feedback on the 2010 RSR dataset 
Category 3:  Models of care and support for HIV and HCV 
Champions:  Ms. Regan Hofmann; Dr. Britt Rios-Ellis 
• Substance abuse treatment for HCV patients 
• Patient education and peer-based solutions for HIV, HCV and sexual health 
• Application of PEPFAR promising practices and innovations (e.g., viral suppression, task 
shifting and peer-based solutions) to domestic HIV/AIDS programs 
• Workforce issues for HIV and HCV prevention and treatment 
Category 4:  Characteristics and priorities of the new NCHHSTP Director 
Champions:  Dr. Jeanne Marrazzo and Mr. Douglas Brooks 
 
With no further discussion or business brought before CHAC, Dr. Marrazzo recessed the 
meeting at 5:18 p.m. on December 11, 2012. 
Kevin Fenton, MD, PhD, FFPH 
Director, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Centers for Disease Control and Prevention 
CHAC Designated Federal Official, CDC 
Opening Session: December 12, 2012
Dr. Fenton conducted a roll call to determine the CHAC voting members, ex-officio members 
and liaison representatives who were in attendance.  None of the voting members publicly 
  
 
DRAFT Meeting Minutes: CDC/HRSA Advisory Committee on 
HIV, Viral Hepatitis and STD Prevention and Treatment 
December 11-12, 2012  ║ Page 43 
disclosed any conflicts of interest for themselves and/or their institutions that were new or 
different than those declared on day 1 of the meeting. 
 
Dr. Fenton verified that the voting members and ex-officio members constituted a quorum for 
CHAC to conduct its business on December 12, 2012.  He reconvened the proceedings at 8:39 
a.m. and welcomed the participants to day 2 of the CHAC meeting. 
Dr. Fenton announced that CHAC meetings are open to the public and all comments made 
during the proceedings are a matter of public record.  He reminded the CHAC voting members 
of their individual responsibility to identify real or perceived conflicts of interest and recuse 
themselves from participating in these matters. 
Jeanne Marrazzo, MD, MPH, CHAC co-Chair 
Professor of Medicine, Harborview Medical Center 
University of Washington 
Dr. Marrazzo joined Dr. Fenton in welcoming the participants to day 2 of the CHAC meeting.  
She announced that the presentations on the previous day covered several important areas:  
implementation of VHAP; the impact of ACA on RWP reauthorization; appropriate use of new 
data (e.g., HRSA’s RSR dataset and CDC’s MMP data); training and support to the workforce to 
assure continued quality care to patients; retention in care and other aspects of the treatment 
cascade; and application of PEPFAR promising practices to domestic HIV/AIDS programs. 
Dr. Marrazzo emphasized that draft recommendations/resolutions proposed by CHAC members 
during the business session would address a number of these key themes.  She concluded her 
opening remarks by briefly reviewing the agenda for day 2 of the CHAC meeting. 
Antigone Dempsey MEd, CHAC co-Chair 
Deputy Director, Knowledge, Transfer and Technical Assistance 
HIV/AIDS Lead, Altarum Institute 
Workgroup Chair 
John Douglas, Jr., MD 
Chief Medical Officer, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Centers for Disease Control and Prevention 
Advice Requested from CHAC by the Sexual Health Workgroup: 
• Does CHAC formally approve a one-year extension for the workgroup to complete its 
activities? 
Update by the CHAC Sexual Health Workgroup
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Ms. Dempsey and Dr. Douglas covered the following topics in their update on the workgroup’s 
recent activities.  After CHAC’s formal adoption of the workgroup’s proposed definition of 
“sexual health” during the May 2012 meeting, a CHAC letter and a joint CHAC/PACHA letter 
were sent to the HHS Secretary on this issue.  The HHS Secretary currently is drafting a 
response to CHAC and PACHA on the sexual health recommendations. 
The workgroup was established in 2010 with a two-year time frame to fulfill its charge, but 
several outstanding issues still need to be addressed.  Most notably, strategies are needed to 
broadly address sexual health.  Strong collaboration is needed with BPHC, providers and health 
departments to translate the sexual health concept into actual practice.  A white paper needs to 
be developed to raise the visibility of sexual health in the field.  The original two-year time frame 
has ended, but the workgroup is now seeking CHAC’s approval to continue its activities for an 
additional one-year period. 
In response to the workgroup’s request, Dr. Fenton explained that workgroups are established 
to complete specific tasks and generate outputs and outcomes over a defined period of time 
(typically 18 to 24 months).  The workgroup is dissolved after fulfilling its charge.  If CHAC votes 
to approve a one-year extension, he urged the workgroup to clearly define its additional goals 
and actually deliver these outputs. 
In follow-up to Dr. Fenton’s comments, Dr. Clanon raised the possibility of renaming the “Sexual 
Health Workgroup” to reflect a more targeted focus on specific tasks during the workgroup’s 
one-year extension.  She noted that the concept of sexual health is broad and is an integral part 
of all aspects of CHAC’s charter to provide guidance on HIV, VH and STD prevention and 
treatment. 
Lindsey Dawson 
Public Policy Associate, The AIDS Institute (TAI) 
Ms. Dawson made the following comments for CHAC’s consideration.  TAI is highly supportive 
of the USPSTF Grade A recommendation for routine HIV screening of adolescents and adults 
15-65 years of age, other persons at increased risk of HIV, and pregnant women.  This positive 
grade change will help make HIV screening a routine component of preventive care.  Most 
notably, high USPSTF grades inform clinical practice and grade changes positively impact 
reimbursement across many payers.  However, progress will be possible only if providers offer 
HIV tests, patients give their consent, and new reimbursement pathways are utilized.  
Public Comment Session
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The grade change will facilitate improvement in coverage of HIV screening through Medicaid, 
Medicare and private insurance.  The field can benefit from leadership by the federal 
government in terms of challenging implementation efforts.  TAI emphasizes the need for 
assistance from CDC to aid in the implementation of the USPSTF recommendations after being 
finalized.  Providers need education on the importance of routine screening and its reimbursable 
status, but facilities, providers and administrators also will need technical assistance related to 
billing and reimbursement practices. 
TAI has observed a patchwork of capabilities, infrastructures and knowledge related to current 
HIV testing reimbursement across the United States.  TAI requests that CDC develop a toolkit 
for implementing these practices.  The toolkit should include case studies, detailed information 
on training, accreditation and coding, and strategies to overcome barriers to reimbursement.  
NASTAD, providers and other parts of the healthcare sector have concluded that the absence of 
the toolkit will serve as a barrier to implementation.  
CDC grantees are accustomed to receiving testing grants and will require assistance in the 
transition to become adept at billing.  CDC testing funds will remain critical due to the 
challenging budgetary climate and increased importance on leveraging limited dollars.  HRSA 
also will need to reach out to its grantees.  Most notably, BPHC will be instrumental in reaching 
out to and advising CHCs on implementing routine screening and billing infrastructures. 
The provision of guidance to RWP grantees on billing and reimbursement practices also will 
help in identifying unknown HIV-positive persons.  This guidance will be integral for CDC and 
HRSA grantees to take advantage of reimbursement changes that will be associated with the 
USPSTF grade change after being finalized.  After the USPSTF Grade A recommendation is 
finalized, routine HIV screening will need to undergo the Medicare coverage determination 
process in order to become a Medicare covered service. 
TAI urges the HHS Secretary to address this issue as soon as the grade is finalized to ensure 
that beneficiaries have access.  Moreover, encouraging state Medicaid programs to cover 
routine screening will be instrumental because HIV disproportionately impacts low-income 
communities.  The grade change is greatly needed and will more closely align the USPSTF 
recommendations with the CDC guidelines, NHAS goals and available science.  Support from 
CDC and HRSA will be critical for implementation. 
Lucy Bradley-Springer, PhD, RN, ACRN, FAAN 
Principal Investigator & Director 
Mountain Plains AIDS Education and Training Center 
Dr. Bradley-Springer made the following comments for CHAC’s consideration.  AETCs are 
positioned at this time to help CHAC advance its agenda for HIV, VH and STD prevention and 
treatment in the upcoming environment of ACA and RWP reauthorization.  AETCs are aware 
that clinicians, prescribers and specialty practitioners are overburdened in meeting the diverse 
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needs of their HIV patients.  As a result, nurses should play a stronger role in these efforts due 
to their medical knowledge and psychosocial communication skills in developing, managing and 
evaluating behavioral health programs in HIV settings.   
Because brief interventions for behavioral problems have not been effective to date, registered 
nurses and other non-clinician professionals should be assigned to address important and time-
consuming issues (e.g., engagement and retention of patients in HIV care, adherence to HIV 
treatment regimens, smoking cessation, health literacy and patient education).  At this time, the 
healthcare sector has a surplus of experienced and trained registered nurses who could be 
utilized in HIV settings.  Overall, nurses are the largest group of healthcare providers in the 
world, but representation of nurses on CHAC is limited to Dr. Parham Hopson. 
Kimberly Miller 
Policy Officer, HIV Medicine Association (HIVMA) 
Ms. Miller made the following comments for CHAC’s consideration.  HIVMA and its four partner 
organizations sent a joint letter to the HHS Secretary dated September 25, 2012.  The purpose 
of the letter was to urge the HHS Secretary to reinstate the Ryan White Clinical Conference.  
Over the past 14 years, this event has served as an important forum for physicians, nurses and 
other members of care teams at RWP-funded clinics to remain informed of the latest 
developments in HIV care and treatment to further advance the field. 
HIVMA and its four partner organizations are requesting CHAC’s support in encouraging the 
HHS Secretary to reinstate the Ryan White Clinical Conference.  The letter was distributed to 
CHAC to guide its decision-making on this issue. 
Daniel Raymond 
Policy Director, Harm Reduction Coalition (HRC) 
Mr. Raymond made the following comments for CHAC’s consideration.  HRC recognizes that 
the current standard of HCV care is based on interferon and has been a major challenge in 
expanding the capacity of providers to deliver HCV treatment.  Experts have predicted that 
interferon-free HCV treatment will not be available for at least 1-2 years.  However, HRC is 
requesting CHAC’s input at this time on a robust system-level approach with the necessary 
practices, supportive payment systems and incentives to enhance the skills and knowledge of 
the workforce in preparation of this change. 
HRC has identified several areas that need to be addressed to prepare for an era of interferon-
free HCV treatment.  A system-level approach should be institutionalized across the healthcare 
system in order for PCPs, internists and infectious disease doctors to take ownership of the 
management and care of HCV patients.  Process and quality measures should be developed to 
benchmark and establish targets for HCV treatment.  Existing models should be reviewed and 
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replicated to the extent possible, such as American Medical Association activities and HIV/HCV 
co-infection efforts. 
Solid registries should be developed with robust cohorts to evaluate innovations in HCV care 
and monitor advancements in clinical practice to improve patient outcomes.  The federal 
government should develop and disseminate rigorous and credible HCV treatment guidelines to 
expand capacity beyond the specialty field and also to navigate and manage patients through 
the pipeline of drugs that will be submitted for FDA approval. 
Strong efforts should be made to bridge the gap in HCV diagnosis.  For example, USPSTF has 
given a Grade C recommendation to CDC’s HCV screening guidelines for the 1945-1965 birth 
cohort, but these persons are at the highest risk for HCV morbidity and mortality and account for 
the majority of cases in the United States.  As a group of experts, CHAC should provide input to 
USPSTF on the critical need to diagnose and monitor HCV on an ongoing basis. 
Michael Shankle, MPH 
Director of Prevention and Policy, HealthHIV 
Mr. Shankle made the following comments for CHAC’s consideration.  HRSA awarded a CoAg 
to HealthHIV to establish the National Center for HIV Care in Minority Communities.  The 
overarching goal of this initiative is to build and expand the clinical and organizational capacity 
of CHCs that primarily serve racial/ethnic minority populations and are not directly funded by 
RWP.  This funding will help CHCs to sustain the provision of HIV care to clients. 
HealthHIV has recruited >100 organizations to participate in this initiative and will award funds 
to up to 30 sub-grantees each year through a competitive process.  The 62 CHCs selected to 
date represent >300 providers nationally with an annual patient population of ~1 million persons, 
including 3,000 PLWH.  This initiative has allowed CHCs to increase their provision of HIV care.  
For example, a CHC in New York has doubled its HIV-positive patient population due to 6-10 
new patients per month. 
CHCs will serve as a major source of primary medical care for a large proportion of newly 
insured persons in the United States who will have access to health insurance after ACA 
implementation.  As a result, clinical training and organizational capacity building will be even 
more important to fully integrate quality HIV care into primary care settings.  CHC providers in 
high-incidence HIV jurisdictions have expressed a strong interest in delivering HIV care. 
HealthHIV welcomes the opportunity to engage CHAC in dialogue on its data, experiences, 
challenges and successes in HIV primary care integration, CHC capacity building and workforce 
development.  HealthHIV’s lessons learned are based on its AETC activities and National 
Workforce Capacity Building Initiative that addresses the HIV workforce shortage by providing 
mentoring and training to HIV care providers. 
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Dr. Fenton and the CHAC members made several remarks in follow-up to the public comments.  
CDC has made a strong commitment to collaborate with the health sector to mobilize providers 
and scale-up HIV testing.  CHAC should identify the strongest drivers to help CDC promote 
change within the provider community in implementing routine HIV screening guidelines (e.g., 
direct funding of HIV treatment and care by HRSA and funding by private insurance and other 
clinical sectors). 
CHAC should provide leadership in extensively engaging professional societies to train their 
members in HIV testing, identify linkage-to-care resources in communities, and offer incentives 
to PCPs at the local level.  CHAC’s outreach efforts also should include AETCs as a primary 
mechanism in rapidly increasing HIV screening after the USPSTF Grade A recommendation is 
finalized. 
Workforce issues have been a recurring theme in CHAC’s discussions and comments by the 
public, but sufficient attention has not been given to this topic to date due to its overwhelming 
scope and magnitude.  To advance this effort, CHAC/PACHA could conduct a joint evaluation of 
ongoing activities at state, local and community levels to advance workforce development.  
CHAC could discuss whether any of the proposed task-shifting options to various practitioners 
could be endorsed as a “safe” or promising practice in U.S.-based settings.  CHAC could draft 
recommendations to engage PLWH with an interest in returning to work without discrimination 
or stigma. 
The co-Chairs and DFOs are aware of the need to develop the 2013 agendas with much more 
time for CHAC to discuss workforce issues.  To assist in this effort, a few CHAC members 
should participate in pre-planning discussions with CDC and HRSA to identify specific workforce 
issues that should be addressed in 2013 and each year thereafter.  For example, CHAC’s 
discussions on workforce issues in 2013 could be limited to reaching goals for HIV screening, 
retention in HIV care, and management of antibiotic-resistant gonorrhea. 
Kaye Hayes, CHAC Ex-Officio Member 
Executive Director, Presidential Advisory Council on HIV/AIDS 
Office of HIV/AIDS and Infectious Disease Policy 
U.S. Department of Health and Human Services 
Douglas Brooks, MSW 
Senior Vice President, Community, Health and Public Policy 
Justice Resource Center 
CHAC Liaison Representative, Presidential Advisory Council on HIV/AIDS 
Update by the PACHA/CHAC Disclosure Workgroup
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Antigone Dempsey MEd, CHAC co-Chair 
Deputy Director, Knowledge, Transfer and Technical Assistance 
HIV/AIDS Lead, Altarum Institute 
Ernest Hopkins, CHAC Member 
Director of Federal Affairs 
San Francisco AIDS Foundation 
Britt Rios-Ellis, PhD, CHAC Member 
Professor and Director, National Council of La Raza 
Center for Latino Community Health, Evaluation and Leadership Training 
California State University, Long Beach 
Advice Requested from CHAC by the PACHA/CHAC Disclosure Workgroup: 
• Does CHAC endorse the guiding principles and policy recommendations for HIV 
disclosure proposed by the workgroup? 
The workgroup members covered the following topics in their update on the workgroup’s recent 
activities.  The NHAS Federal Implementation Plan outlined specific tasks for PACHA and 
CHAC.  PACHA was tasked with developing recommendations to promote and normalize safe 
and voluntary disclosure of HIV status in various contexts and circumstances.  CHAC was 
tasked with soliciting public input and making recommendations to normalize and promote safe 
and voluntary disclosure of the HIV status of individuals.  HRSA would be responsible for 
publishing the recommendations. 
PACHA/CHAC initially raised several concerns that would need to be addressed to fulfill their 
charge.  Most notably, language in NHAS appeared to have a bias in favor of disclosure.  
Potentially negative consequences and ramifications for individuals who disclose their status 
and the opposite bias from a civil rights perspective also would be important issues to address. 
The next steps for PACHA/CHAC in this process were to gather information to determine the 
overarching goal of the disclosure recommendations, necessary competencies, legal context, 
target audiences, and HIV criminalization issues.  PACHA/CHAC then co-chaired a Disclosure 
Summit in June 2012 to ground the disclosure activities in theory, expertise and experience; 
create a framework of guiding principles and policy recommendations that would foster an 
environment allowing for safe and voluntary disclosure; and synthesize and build consensus. 
The summit participants represented multiple disciplines, cross-cutting partners and diverse 
thought leaders in both public and private sectors, including PLWHA, community advocates, 
social scientists, medical ethicists, researchers, health providers, education leaders, lawyers 
and policymakers.  The summit resulted in the development of two major outputs:  (1) a set of 
guiding principles for recommendations on safe and voluntary disclosure of HIV status and (2) a 
  
 
DRAFT Meeting Minutes: CDC/HRSA Advisory Committee on 
HIV, Viral Hepatitis and STD Prevention and Treatment 
December 11-12, 2012  ║ Page 50 
set of short-/long-term policy recommendations to promote safe and voluntary disclosure of HIV 
status in the United States. 
The summit participants agreed on a number of key themes to develop the guiding principles 
and policy recommendations.  HIV disclosure impacts the entire life and various networks of 
individuals, including their family, social, professional, service and sexual networks.  Disclosure 
is not a single discrete event, but rather is an ongoing process that spans a lifetime.  Disclosure 
is associated with both benefits and risk. 
The personal benefits of disclosure include social support, mental health services, access to 
care, treatment adherence, and the ability to obtain benefits and secure legal protections.  The 
group benefits of disclosure include opportunities for dialogue, increased visibility and 
empowerment, connections and group cohesiveness, and reduction in discrimination and 
stigma. 
The risks of disclosure include negative reactions, adverse decision-making, potential re-
disclosure, loss of privacy, and possible criminal prosecution.  Overall, the most important 
element is for individuals to make an informed decision on disclosure that is best for their 
personal situation in a particular context. 
The organizational structure of the summit allowed the participants to achieve the expected 
outcomes.  On day 1, the full group of participants created the guiding principles.  On day 2, the 
participants divided into teams to craft policy recommendations in three areas:  criminalization/ 
legal issues, health systems issues, and family/societal issues.  The full group reached 
consensus on the guiding principles and policy recommendations. 
The workgroup presented the HIV disclosure guiding principles and policy recommendations 
that would be placed on the floor for CHAC’s formal vote during the business session.  The 
workgroup noted that this language replaces the October 26, 2012 draft report that was 
previously distributed to CHAC. 
PREAMBLE 
We are committed to ending the HIV/AIDS epidemic.  We are committed to honoring the 
strength and resilience of people living with HIV/AIDS and their invaluable role in the nation’s 
ongoing fight against the epidemic.  We are committed to ensuring and protecting the right and 
ability of all people to live full, healthy lives. 
With these commitments firmly in mind, we recognize and respect: 
• the ultimate autonomy of each individual faced with the opportunities and challenges of 
disclosing her or his HIV status; 
• that disclosure of HIV status is not a single, discrete event, but rather an ongoing 
process spanning a lifetime and myriad contexts; and 
• that the disclosure process necessarily involves multiple parties.  
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These commitments and the recognition of the characteristics of the disclosure process 
informed the development of the guiding principles for our discussions and our ultimate 
recommendations.  While this document is focused on the NHAS directives on HIV disclosure, 
the group also acknowledges that disclosure of all STIs promotes greater communication and 
sexual health. 
GUIDING PRINCIPLE 1: Society has an obligation to create a safe environment for HIV 
disclosure. 
There is an obligation and a responsibility for society to create a safe environment for people to 
voluntarily disclose their HIV status as well as other sexually transmissible infections.  
Accordingly, any laws and policies that create disincentives to an individual’s safe and voluntary 
disclosure of her or his HIV status, e.g., by increasing HIV stigma and discrimination, should be 
eliminated.  All relevant Federal, state and local laws and policies should incorporate the current 
state of medical science, best-practices in public health, and evidence-based strategies and 
priorities for effectively addressing the HIV epidemic and should strive to create and maintain 
resources and environments conducive to safe and voluntary disclosure. 
GUIDING PRINCIPLE 2: Discussion of HIV and STI status is important. 
Confidential and ongoing communication about HIV status and other relevant sexual health 
conditions (both for those living with HIV and those whose current status is negative or 
unknown) is essential for individual, family, and community health.  An environment that allows 
for safe, voluntary disclosure empowers persons living with HIV to:  1) access support and care 
without fear of stigma or persecution; and 2) participate in the organizations and mechanisms of 
policy, to which they bring invaluable lived-experience.  Ultimately, an environment that protects 
the ability to engage in safe and voluntary disclosure enables all community members to make 
informed decisions in regard to their own health and conduct. 
GUIDING PRINCIPLE 3: The circumstances and context of disclosure must be respected. 
A complex constellation of cultural and social factors influences every individual’s ability to 
safely disclose her or his HIV status.  These factors must be respected in order to create 
environments that facilitate safe and voluntary disclosure.  Only if we understand and appreciate 
the external pressures militating against safe, voluntary disclosure, can we create solutions that 
allow for all people to access the support, treatment and education resources that they need 
and deserve.  
SHORT-TERM POLICY RECOMMENDATIONS 
1. HHS and other federal funders should devote a portion of currently funded programs to 
facilitate campaigns and education on safe and voluntary disclosure that encourages an 
understanding of HIV in the context of a range of sexually-transmissible diseases that 
can have a profound impact on health and life.  Issues of disclosure should be infused in 
prevention campaigns.  Federal funders should be encouraged to conduct research on 
what is already known related to effective programs and how to apply their research 
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findings. 
2. Federal funders should develop and/or disseminate quantitative and qualitative research 
agenda and fund studies on the benefits and challenges of disclosure. 
3. The Surgeon General should write a letter to the American People containing up-to-date 
information about HIV/AIDS and the importance of frank discussions about maintaining 
sexual health.  Much has changed since Surgeon General Koop’s 1988 letter; a new 
letter will help correct many persistent misconceptions about HIV, its transmission, and 
the prognosis for those whose infection if detected early and are provided with 
appropriate access to HIV-related healthcare. 
4. The Secretary of Health and Human Services should appoint an HHS representative to 
work with the associate attorney general to create a working group to examine laws and 
policies that discriminate against people with HIV and formulate recommendations for 
the elimination of those laws, and develop recommendations for laws and policies that 
would support and protect people living with and vulnerable to HIV. 
5. A dedicated position should be established within the Office of the Associate Attorney 
General for HIV Law and Policy. 
LONG-TERM POLICY RECOMMENDATIONS 
1. HHS and medical providers should prioritize disclosure support as a component of 
mental health services within clinical settings.  Disclosure education, training and 
support should be included under the definition of “peer navigator/support.”  Recognizing 
that disclosure is a continuous and voluntary process, we need to fund supportive work 
around disclosure in the clinical setting over a person’s lifespan.  In addition, the 
following approaches should be supported: 
• Part of the clinical care model should include a comprehensive discussion of HIV and 
STI disclosure outcomes with a trauma-informed approach to care.  Approaches to 
disclosure in the clinical setting which merely involve informing the newly-diagnosed 
of the existence of a law mandating disclosure and/or advising and admonishing the 
person to disclose to all sexual partners should be discouraged. 
• To support this, AETCs should be allowed to train peers and count peer training.  In 
addition, medical professionals need to be trained.  Accordingly, nursing and medical 
education should include skills building on supporting and facilitating disclosure. 
2. HHS should develop sex-positive prevention messages rooted in evidence-based 
research but also reflecting and tailored to people’s real lives; create culturally relevant 
messages developed by people living with HIV. 
3. HHS should develop ways to encourage and incentivize states to address state and 
local laws that create barriers to disclosure of HIV status and access to care. To further 
support this, we recommend that HHS conduct an objective analysis on the impact of 
these laws on access to testing and care. 
The workgroup’s next steps will be to collaborate with HHS on devising strategies to implement 
the HIV disclosure recommendations.  The focus initially will be placed on the updated Surgeon 
  
 
DRAFT Meeting Minutes: CDC/HRSA Advisory Committee on 
HIV, Viral Hepatitis and STD Prevention and Treatment 
December 11-12, 2012  ║ Page 53 
General letter and guidance directed to the Department of Justice.  The workgroup will then 
prioritize the remaining recommendations for implementation. 
CHAC applauded the workgroup for its outstanding efforts in addressing the extremely complex 
issue of HIV disclosure and formulating well-articulated, actionable and pragmatic guidance to 
HHS.  The CHAC members made three key suggestions for the workgroup to consider in 
finalizing the recommendations. 
• The research recommendation should be expanded to encourage HHS to compile 
examples of state HIV criminalization laws that hinder persons from receiving HIV 
testing.  Solid data in this area will be necessary to empower states to change their 
existing laws. 
• The term “sex-positive” should be clarified to ensure that HHS is given clear guidance in 
order to implement the recommendation. 
• New language should be included in the recommendations for HHS to explore strategies 
for persons to disclose their HIV status through the Internet and social media platforms.  
Most notably, Ms. Dempsey and Mr. Brooks will co-host a Twitter chat (#HIVdisclosure) 
on December 14, 2012 at 11:00 a.m. EST. 
 
Dr. William Grace, ex-officio member for NIH, responded to one of CHAC’s suggestions.  NIH 
currently is funding 77 research grants related to HIV disclosure both domestically and 
internationally.  Some of the domestic grantees are analyzing state laws to determine the impact 
of disclosure on HIV testing. 
Update by the CHAC Ryan White Reauthorization Workgroup
Kathleen Clanon, MD 
Director, Division of HIV Services 
Alameda County Medical Center 
CHAC Member 
Ernest Hopkins 
Director of Federal Affairs 
San Francisco AIDS Foundation 
CHAC Member 
Advice Requested from CHAC by the Ryan White Reauthorization Workgroup: 
• What is CHAC’s input on the reauthorization issues articulated by the workgroup? 
• What is CHAC’s guidance on the workgroup’s most useful role in advising HRSA/HAB in 
light of its role in reauthorization discussions? 
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Dr. Clanon and Mr. Hopkins covered the following topics in their update on the workgroup’s 
recent activities.  The workgroup was established during the May 2012 meeting with a formal 
charge of developing recommendations on RWP reauthorization for CHAC’s consideration and 
potential adoption.  The workgroup’s guidance would be designed to reflect evolving care needs 
in the context of ACA implementation.   
Following the May 2012 CHAC meeting, the workgroup held one face-to-face meeting and three 
teleconferences to identify potential issues to cover in its recommendations: 
• potential new care models (e.g., primary care and specialist co-management); 
• definition of the “HIV specialty medical home;” 
• strategies to share best practices in successful care linkage; 
• meaningful use of local epidemiological and laboratory data; and 
• expansion of the prevention mandate in treatment and other care settings. 
HAB staff has actively participated in the workgroup’s activities and provided technical guidance 
in three key areas:  (1) the intersection between RWP and ACA, (2) advice and requests to 
HRSA on strategies to keep CHAC and RWP grantees informed, and (3) updates on the status 
and availability of data and information to RWP grantees. 
HRSA opened a public comment period in July 2012 to obtain input on RWP reauthorization 
issues that potentially could be impacted by ACA.  Based on this feedback, the workgroup 
developed a list of issues the HHS Secretary should consider in any discussions on RWP 
reauthorization. 
Because workgroups have no mechanism for their parent committees to formally approve 
recommendations in between public meetings, two CHAC members (Drs. Kathleen Clanon and 
Steven Johnson) submitted the list of issues in a letter to HRSA as independent RWP medical 
providers in order to maintain momentum of this effort.  The July 31, 2012 letter to Dr. Mary 
Wakefield, Administrator of HRSA, was distributed to CHAC for review.  The workgroup’s list of 
issues covers five key recommendations on RWP reauthorization 
1. Reevaluate the definition and application of the “payer of last resort.” 
2. Ensure that prioritization of “core medical services” (i.e., the 75/25 rule) promotes access 
to a comprehensive program of HIV care and services. 
3. Invest in the commitment to reach an “AIDS-Free Generation” by expanding access to 
the RWP model. 
4. Improve the allocation of resources to better target funds to locations where PLWH 
receive HIV care.  Use client-level data to determine inputs to this formula. 
5. Re-envision the Planning Council to monitor service gaps, service utilization and HIV-
related disparities rather than funding allocations. 
The workgroup cited language in the 1990 RWP authorization legislation to support the payer of 
last resort recommendation:  “CARE Act grant funds cannot be used to make payments for any 
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item or service if payment has been made or can reasonably be expected to be made with 
respect to that item or service under any State compensation program, under an insurance 
policy, or under any Federal or State health benefits program; or by any entity that provides 
prepaid health care.” 
 
The workgroup’s next steps will be to address various options for RWP reauthorization (e.g., no 
reauthorization, technical revisions or full reauthorization); explore strategies to facilitate 
integration of RWP with new insurance options; and develop a large-scale vision for the future. 
 
CHAC made several comments and suggestions for the workgroup to consider in refining its 
draft recommendations on RWP reauthorization. 
 
• The workgroup should expand the payer of last resort recommendation to specifically 
address payment to the Indian Health Service to meet the unique HIV/AIDS care and 
treatment needs of Native Americans.  Most notably, Native Americans currently are 
eligible to access both RWP clinics and ADAP programs to obtain medications. 
• The workgroup should ensure that its recommendations on RWP reauthorization to HHS 
and HRSA are aligned with those of other organizations and constituencies to the extent 
possible.  A cohesive approach will be needed to promote similar legislative agendas 
and convey the same messages in terms of ACA implementation for PLWHA. 
• The workgroup should revise its recommendations to more strongly focus on integration 
of prevention into care.  For example, the existing structure for direct care, provision of 
PrEP by RWP providers, and implementation of other strategies would be excellent 
drivers for HIV testing in CHCs.  
• Lessons learned and emerging practices from interagency grassroots initiatives (e.g., 
ECHPP, the 12 Cities Project and CAPUS) should be compiled to inform the language, 
policies and new directions of RWP reauthorization. 
At the conclusion of the discussion, the workgroup confirmed that CHAC’s suggestions and 
comments to finalize the draft recommendations on RWP reauthorization would be considered.  
The workgroup also would take responsibility for responding to the questions Dr. Slifkin posed 
on the previous day regarding the impact of ACA on RWP and PLWHA. 
Update by the CHAC Viral Hepatitis Workgroup
Antigone Dempsey MEd, CHAC co-Chair 
Deputy Director, Knowledge, Transfer and Technical Assistance 
HIV/AIDS Lead, Altarum Institute 
Advice Requested from CHAC by the Viral Hepatitis Workgroup: 
• What are CHAC’s potential next steps to address the new USPSTF HCV testing 
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recommendations? 
Ms. Dempsey covered the following topics in her update on the workgroup’s recent activities.  
The workgroup was established during the May 2012 meeting and formally charged with three 
major tasks.  First, opportunities will be identified within CDC and HRSA to improve and 
coordinate prevention, screening, linkage to care, and treatment for persons with chronic HBV 
and HCV infection. 
Second, the current state and adequacy of surveillance measures will be assessed for both 
acute and chronic hepatitis, core indicators and quality measures to (1) determine whether 
existing measures are adequate to evaluate gaps, barriers and progress in implementing CDC’s 
HCV screening recommendations for the 1945-1965 birth cohort and other elements of VHAP 
and (2) assess missed opportunities for earlier diagnosis to prevent morbidity and mortality.  
Third, the implications of ACA on VHAP will be evaluated. 
To fulfill its broad charge, the workgroup identified and engaged ~10 expert consultants, 
policymakers, medical providers and community members/advocates with a strong interest in 
HBV and HCV.  CDC, HRSA and HHS are represented on the workgroup as well.  The 
workgroup held its first two meetings in November and early December 2012 to prepare for the 
current CHAC meeting and determine priority issues for the next six months. 
During its November 2012 meeting, the workgroup agreed to prioritize five key activities over 
the next six months: 
• focus on the HCV testing recommendations; 
• identify opportunities within CDC and HRSA to improve and coordinate prevention, 
screening, linkage to care, and treatment for persons with chronic HBV and HCV with an 
emphasis on identifying locations where individuals receive treatment; 
• support basic messaging related to enrolling persons into care; 
• focus on hepatitis testing recommendations in the context of ACA; and 
• focus on workforce issues. 
During its December 2012 meeting, the workgroup noted that the public comment period for the 
draft USPSTF HCV testing recommendations would close on December 24, 2012.  Based on 
CHAC’s formal approval during the business session, the workgroup would submit the following 
language as CHAC’s public comment to USPSTF. 
Both CDC and the USPSTF conclude with moderate certainty that HCV testing is of 
benefit to HCV-infected persons.  While both sets of recommendations agree on the 
rationale for and value of HCV screening, the USPSTF distinction of a Grade C for birth 
cohort screening does not reflect the supportive data and will limit the extent to which 
this recommendation is implemented in actual practice.  HCV testing with linkages to 
appropriate care and treatment can benefit HCV-infected persons regardless of the 
approach to testing.  Accordingly, both birth cohort and risk-based strategies warrant a 
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Grade B recommendation.  We are concerned that the “suggestion for practice” 
corresponding to the grade C designation will not allow for the recommendation to be 
applied routinely during care of this large population of persons infected with HCV in the 
distant past and now at greatest risk for HCV morbidity and mortality.  Many of these 
persons either lack the ability to cover the cost of this screening themselves, who are 
uninsured, or whose insurance coverage will not pay for the screening test.  Many of 
these persons will not be reached by risk based testing alone. As stated by USPSTF, 
“Many individuals with chronic HCV infection are unaware of their condition.  A risk-
based approach may miss detection of a substantial proportion of HCV in the birth 
cohort.”  This will undermine the opportunity presented by the CDC’s strong 
recommendation to make screening routine for this birth cohort to identify, for the first 
time, the large proportion of undiagnosed HCV infection in U.S. adults, and to intervene 
with effective care and treatment.  We call on the USPSTF to reconsider this grade and 
elevate the recommendation for routine birth cohort screening to grade B. 
CHAC Business Session
Antigone Dempsey MEd, CHAC co-Chair 
Deputy Director, Knowledge, Transfer and Technical Assistance 
HIV/AIDS Lead, Altarum Institute 
Jeanne Marrazzo, MD, MPH, CHAC co-Chair 
Professor of Medicine, Harborview Medical Center 
University of Washington 
Ms. Dempsey and Dr. Marrazzo opened the business session and called for CHAC’s review, 
discussion or formal action on the following topics. 
Topic 1: Adoption of the Draft CHAC Meeting Minutes 
Dr. Marrazzo entertained a motion for CHAC to approve the previous meeting minutes.  A 
motion was properly placed on the floor and seconded by Drs. Marjorie Hill and Kenneth Mayer, 
respectively, for CHAC to approve the previous meeting minutes. 
CHAC unanimously adopted the Draft May 8-9, 2012 Meeting Minutes with no changes or 
further discussion. 
Topic 2:  CHAC Sexual Health Workgroup 
Champions: Workgroup Members 
The following motion was properly placed on the floor and seconded by Ms. Antigone Dempsey 
and Dr. Kathleen Clanon, respectively. 
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CHAC recommends an extension of the Sexual Health Workgroup’s original two-year 
time frame for one additional year.  During the one-year extension, the workgroup will 
focus on providing advice to CDC and HRSA in two key areas:  (1) implementation of a 
sexual health framework approach and (2) development of strategies to disseminate 
information about sexual health. 
CHAC unanimously approved the resolution. 
Topic 3:  PACHA/CHAC Disclosure Workgroup 
Champions: Workgroup Members 
The following motion was properly placed on the floor and seconded by Ms. Antigone Dempsey 
and Mr. Tommy Chesbro, respectively. 
CHAC recommends formal adoption of the workgroup’s report that outlines guiding 
principles and policy recommendations for HIV disclosure and submission of the report 
to the HHS Secretary.   
CHAC unanimously approved the resolution. 
Topic 4:  Viral Hepatitis Workgroup 
Champions: Workgroup Members 
 
The following motion was properly placed on the floor and seconded by Ms. Antigone Dempsey 
and Mr. Ernest Hopkins, respectively. 
 
CHAC recommends formal adoption of the workgroup’s draft language on the USPSTF 
Grade C recommendation for HCV screening of the birth cohort and submission of this 
language to USPSTF as a public comment from CHAC. 
 
CHAC unanimously approved the resolution. 
 
Topic 5:  New NCHHSTP Director 
Champions: Jeanne Marrazzo, MD, MPH; Douglas Brooks, MSW 
The CHAC members discussed and offered several suggestions to refine the resolution Dr. 
Marrazzo and Mr. Brooks drafted regarding the new NCHHSTP Director.  At the conclusion of 
the discussion, the following motion was properly placed on the floor and seconded by Drs. 
Carlos del Rio and Marjorie Hill, respectively, for CHAC to formally adopt and submit the 
following resolution to the CDC Director. 
CHAC applauds the vision, intellect, commitment and care that Dr. Kevin Fenton has 
brought to his leadership of the CDC National Center for HIV/AIDS, Viral Hepatitis, STD 
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and TB Prevention.  A hallmark of Dr. Fenton’s tenure was his tireless effort to address 
issues of overarching importance for prevention and treatment of HIV/AIDS, viral 
hepatitis and STD, including Health Equity and Social Determinants of Health, 
Prevention through Healthcare, and Sexual Health.   
As the search commences for a new Director of the Center, we encourage the CDC 
Director and search committee to select a candidate who will continue to prioritize a 
public health approach that is holistic and who understands the need to consider the 
interrelated and interdependent systems that impact peoples’ lives, particularly those 
most affected by these preventable and treatable diseases.  This focus on health equity 
and prioritization of resources where they are most needed and have the most impact is 
especially critical as we transition into the era of the Affordable Care Act, which we hope 
will result in increased access to health care and ultimately improve population health.  
For this transition to be successful, we believe that both CDC and HRSA need to 
recognize the success of Dr. Fenton’s efforts to institutionalize these priorities, and that 
his successor build on them.  An important part of the work of this position is to align 
public health and primary care priorities, and to continue the momentum for addressing 
these issues in the context of CDC’s and HRSA’s scientific and programmatic work. 
CHAC unanimously approved the resolution. 
Topic 6:  Late Diagnosis of HIV 
Champion: Carlos del Rio, MD 
The CHAC members discussed and offered several suggestions to refine the resolution Dr. del 
Rio drafted regarding late diagnosis of HIV.  At the conclusion of the discussion, the following 
motion was properly placed on the floor and seconded by Dr. Carlos del Rio and Mr. Ernest 
Hopkins, respectively, for CHAC to formally adopt and submit the following resolution to the 
HHS Secretary. 
The U.S. Department of Health and Human Services’ (HHS) recent Antiretroviral 
Therapy (ART) Treatment Guidelines (March 2012) now recommend ART treatment 
regardless of CD4 count both for benefit to the individual as well as to prevent HIV 
transmission.  CHAC expresses its concern about the challenge that late diagnosis of 
HIV continues to have on long-term outcomes of persons with HIV in the United States 
as well as ongoing transmission.  CHAC recommends that the Secretary of HHS 
convene a group to examine the causes of late diagnosis of HIV, and proactively 
examine these cases as “sentinel events” or “failures of early detection” that highlight 
failures of the health system that need to be addressed. 
CHAC unanimously approved the resolution. 
Topic 7:  CDC’s Response to the IOM Report 
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Champion: Jennifer Kates, PhD 
The CHAC members discussed and offered several suggestions to refine the resolution Dr. 
Kates drafted regarding CDC’s response to the IOM report.  At the conclusion of the discussion, 
the following motion was properly placed on the floor and seconded by Drs. Jennifer Kates and 
Steven Johnson, respectively, for CHAC to formally adopt and submit the following resolution to 
the CDC Director.  
CHAC endorses the recent Institute of Medicine Report, Monitoring HIV Care in the 
United States: A Strategy for Generating National Estimates of HIV Care and Coverage 
(October 2012).  The report was commissioned by the White House Office of National 
AIDS Policy to provide an enhanced means of assessing the effect of the National 
HIV/AIDS Strategy and the Affordable Care Act on care received by persons with HIV.  
In addition, CHAC also requests that CDC report back to the CHAC by its next meeting 
with input on recommendations in the IOM report specific to CDC, particularly the 
recommendations related to the CDC Medical Monitoring Project.  
CHAC unanimously approved the resolution. 
Topic 8:  New Data Workgroup 
Champion: Jennifer Kates, PhD 
The following motion was properly placed on the floor and seconded by Dr. Jennifer Kates and 
Mr. Ernest Hopkins, respectively. 
CHAC recommends the formation of a new workgroup to work with HRSA and CDC on 
assessing emerging data that should directly inform the implementation of the Affordable 
Care Act, especially as it relates to prevention interventions and the delivery of care in 
clinics receiving Ryan White funds and in Community Health Centers. 
CHAC unanimously approved the resolution. 
Ms. Dempsey urged the new Data Workgroup to prioritize two key tasks in its initial discussions:  
(1) clarify and refine its formal charge and (2) engage HAB in discussions on additional data 
runs to perform with the RSR dataset.  The following CHAC members volunteered to serve on 
the workgroup: 
• Co-Chairs:  Jennifer Kates, PhD; Jeanne Marrazzo, MD, MPH 
• Members:  Kathleen Clanon, MD; Angelique Croasdale, MA; Carlos del Rio, MD; Steven 
Johnson, MD 
Topic 9:  Ongoing Support of In-Person CHAC Meetings 
Champion: Kathleen Clanon, MD 
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Drs. Fenton and Parham Hopson made two announcements that are likely to impact the 
function of future CHAC meetings.  First, the White House issued a mandate for all federal 
agencies to reduce the number of face-to-face meetings of their Federal Advisory Committees 
(FACs) by increasing the use of webinars and other virtual technologies.  Second, HRSA’s 
ability to continue to support travel for all HRSA-appointed CHAC members and key HRSA staff 
to attend CDC-centric meetings in Atlanta is in jeopardy due to severe budget cuts. 
In response to these announcements, the following motion was properly placed on the floor and 
seconded by Drs. Kathleen Clanon and Britt Rios-Ellis, respectively, for CHAC to formally adopt 
and submit the following resolution to the CDC Director and HRSA Administrator. 
Because CHAC advises two federal agencies instead of one, CHAC strongly feels that 
continuation of two face-to-face meetings per year is necessary.  Due to the strong 
intersection and integration of CDC and HRSA as expressly recommended in the 
National HIV/AIDS Strategy, CHAC further believes that its HRSA-appointed members 
must continue to be given travel support to attend CDC-centric meetings in Atlanta. 
CHAC unanimously approved the spirit, concept and intent of the resolution. 
Dr. Clanon would refine the resolution with background information on CHAC’s unique role of 
advising two federal agencies.  The revised resolution would be circulated to CHAC for review 
before submission to the CDC Director and HRSA Administrator.  Dr. Parham Hopson and the 
new NCHHSTP Director would use the final resolution to justify continued travel support for two 
face-to-face CHAC meetings per year. 
Topic 10:  Future Agenda Items 
CHAC proposed the following presentations, overviews or updates to place on future meeting 
agendas. 
• CDC:  “Meet-and-greet” session with the new NCHHSTP Director 
• CMS:  Overview of CMS’s role in the current care model and CMS’s efforts to include 
prevention in the model 
• Guest Presenters:  Presentation by Dr. Michael Mugavero or other experts who are 
conducting research to determine specific reasons for PLWH disengaging from care 
(e.g., physical barriers or provider-related issues) 
• Panel Presentation on Workforce Issues: 
o Ongoing activities with AETCs, Prevention Training Centers, ancillary providers and 
specialty medical groups (e.g., National Hispanic Medical Association and National 
Medical Association) 
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o Preliminary results of the HIV Workforce Study (HAB) and complex workforce issues 
(Mr. Edward Salsberg, Director, National Center for Health Workforce Analysis, 
HRSA Bureau of Health Professions) 
o Status report on activities conducted by the 12 Cities Project and CAPUS grantees 
o Existing capacity and skills of the workforce (e.g., current training approaches and 
disease-specific issues) 
o Field trip to the Ryan White HIV Clinic in Atlanta if time permits 
CHAC agreed that due to the overwhelming scope and magnitude of workforce issues, the 
meeting format would need to be restructured to accommodate this agenda item.  For the first 
meeting in 2013, the morning session would be devoted to key updates from CDC and the 
entire afternoon session would be devoted to CHAC’s in-depth discussion of workforce issues 
with an emphasis on prevention.  The same format would be repeated for the second meeting in 
2013, but HRSA would present key updates during the morning session and CHAC’s in-depth 
discussion of workforce issues during the afternoon session would focus on care and treatment. 
Topic 11:  Action Items 
CHAC reviewed the action items that were raised over the course of the meeting. 
• Dr. Britt Rios-Ellis agreed to co-chair the Sexual Health Workgroup with Ms. Antigone 
Dempsey. 
• The HRSA and CDC Committee Management Specialists (Ms. Shelley Gordon and Ms. 
Margie Scott-Cseh) will obtain links to the two recent IOM reports from Drs. Jennifer 
Kates and/or Carlos del Rio for distribution to the entire CHAC membership. 
• Dr. Carlos del Rio will organize a field trip to the Ryan White HIV Clinic in Atlanta during 
the next CHAC meeting if time permits.  He also offered the facilities at the Emory 
University Rollins School of Public Health for persons who are unable to attend the next 
CHAC meeting to participate in the proceedings remotely. 
Topic 12:  Ongoing Assessment of the CHAC Meeting Format 
Dr. Marrazzo solicited additional feedback from CHAC to aid the co-Chairs and DFOs in their 
ongoing assessment of the meeting format.  CHAC’s insights and perspectives on the current 
meeting fell into three major categories. 
Category 1: Preparation for the Business Session 
CHAC made tremendous progress with the new format during the May 2012 meeting in terms of 
being more efficient and productive and providing HHS, CDC and HRSA with clearer and more 
substantive guidance.  However, day 1 of the current meeting appeared to regress to the old 
format of a dense agenda with numerous and lengthy presentations and limited time for CHAC’s 
discussion.  This structure did not allow the CHAC members to engage in meaningful dialogue 
and express their thoughts on specific topics during the meeting. 
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After day 1 of the meeting has been recessed, the new format allows the champions and their 
CHAC colleagues to meet in small groups in the evening to draft resolutions/recommendations.  
However, the timeline of this process is problematic.  Most notably, the productivity of the 
members has decreased by this time and their memories are not as sharp after listening to a full 
day of presentations.  The co-Chairs and DFOs should consider two potential options to 
improve the timeline for CHAC members to prepare for the business session. 
• Option 1:  The CHAC members should divide into small groups for 15-30 minutes after 
each series of presentations has been made on a particular issue or theme to discuss 
the information and begin drafting resolutions or recommendations in “real time” during 
meetings. 
• Option 2:  Future agendas should be structured with less and shorter presentations on 
day 1 of the meeting.  By 3:30 or 4:00 at the latest, CHAC should begin preparing for the 
business session by agreeing on topics that need formal resolutions/recommendations 
and identifying champions and other members to take responsibility for each issue. 
Category 2: Meeting Materials 
Stronger efforts should be made for CHAC to become a “greener” committee by reducing the 
volume of printed meeting materials.  For example, CD-ROMs, e-mail attachments and web 
links should be used to provide CHAC members with documents in the meeting binders (e.g., 
PowerPoint slide sets, meeting minutes, background information and recent publications). 
However, “late-breaking” slide sets that are circulated in print during meetings should be 
formatted with 2 rather than 3 slides per page for easier reading. 
Speakers should format their PowerPoint slide sets with two key bullet points at the beginning of 
their presentations:  (1) the purpose, intent or rationale for placing the topic on the agenda and 
(2) clear guidance requested from CHAC if a formal resolution or recommendation needs to be 
drafted or specific action needs to be taken. 
Category 3: Retention of the Membership 
Each CHAC member must make a strong commitment to remain present for the entire length of 
each meeting.  Most notably, FACs are prohibited from formally voting on issues without a 
quorum.  To assist in this effort, CDC and HRSA will finalize and inform the CHAC members of 
the next meeting date with as much advance notice as possible and also will attempt to adjourn 
future meetings by 12:00 p.m. on day 2. 
Topic 13:  Parting Remarks to Dr. Kevin Fenton 
Editor’s note:  The quotes outlined below were made over the course of the 1.5-day meeting, 
but are compiled in one section to honor Dr. Fenton’s seven-year tenure as the NCHHSTP 
Director and the CHAC DFO for CDC. 
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• Dr. Kenneth Mayer:  “Kevin, I want to salute you on your superb leadership and really 
thank you for your service.  Working with you and your staff has been unparalleled in 
terms of the level of cooperation.” 
• Ms. Regan Hofmann:  “Kevin, thank you for your superb leadership.  We will miss you 
very much.” 
• Dr. Marjorie Hill:  “We will miss you, Dr. Fenton.  There’s a long list of your 
accomplishments, but I think the transfer of Adolescent Health into the Center was a 
significant change and is making headway in terms of some of the issues we are talking 
about.” 
• Dr. Jennifer Kates:  “I’m sad that you’re not going to be here at my future meetings.  We 
really thank you for everything you’ve done.” 
• Mr. Douglas Brooks:  “Dr. Fenton, we all appreciate you for various reasons and one of 
mine is for your unyielding leadership on including the social determinants of health as 
we examine the lives of people.  As a social worker, I greatly appreciate that and your 
social worker’s doctorate.” 
• Dr. Rima Khabbaz:  “I suspect you all share my mixed feelings heading into this 
transition.  I’m very excited for Kevin for his opportunity and new position in the U.K.  
He’s going back home in some ways and he will shape a new agency there.  At the 
same time, we’re going to miss him; that’s an understatement.  He’s been a great leader 
and a great colleague.  I have learned from him.  I’m really sad to see him go back 
across the pond.” 
• Dr. Jonathan Mermin:  “Thank you, Kevin, for your leadership.” 
• Dr. Jeanne Marrazzo:  “Kevin, I think I speak for everybody when I say we’ll miss you as 
we welcome John.  We’ll miss you more than our words can express, which I think has 
been coming across pretty sincerely and intensely.” 
Overview of Social Media Opportunities for CHAC
Jeanne Marrazzo, MD, MPH, CHAC co-Chair 
Professor of Medicine, Harborview Medical Center 
University of Washington 
Antigone Dempsey MEd, CHAC co-Chair 
Deputy Director, Knowledge, Transfer and Technical Assistance 
HIV/AIDS Lead, Altarum Institute 
Dr. Marrazzo and Ms. Dempsey presented an overview of strategic and innovative social media 
opportunities for CHAC to broadly communicate and widely engage the public in its activities.  
Social media are web-based and mobile tools and activities that shift communication to 
interactive dialogue and integrate technology and social interaction. 
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Each day, Facebook users “like” and “comment” on items 3.2 billion times per day and watch 
500 years of YouTube videos.  Each minute, Facebook receives 208,000 uploaded images and 
YouTube receives 60 hours of uploaded videos.  Each second, 11 new Twitter profiles are 
created.  The number of wireless devices that are used in the United States at this time is 
greater than the number of persons in the U.S. population. 
 
Social media are used to complement traditional communication platforms, share information in 
new spaces, connect with new audiences, encourage engagement and interaction with the 
content, and empower individuals to make more informed decisions.  For example, the CDC 
iPad application provides outstanding access to MMWR articles, Vitalsigns Reports and other 
important prevention data. 
 
Social media planning should be strategic in order to achieve communication planning inputs, 
such as reaching and engaging primary/secondary audiences and determining communication 
objectives (e.g., raising awareness, increasing knowledge or influencing/persuading).  For 
example, the PACHA website has served as a primary influencer by increasing the visibility of 
national HIV/AIDS-related efforts.  Communication objectives should be designed to lead to 
effective strategies and tactics for: 
 
1. community building; 
2. calls to action; 
3. creation of interest and excitement 
4. listening and monitoring 
5. audience engagement; 
6. increased reach; and 
7. general awareness and promotion of the issue in the news.   
A small group of CHAC members had offline discussions with CDC and agreed that a focus on 
communication objectives 5-7 would be most relevant and feasible for CHAC’s mission.  
Agreement was reached that CHAC’s cross-media strategies should include Facebook, Twitter 
and video conferencing/webinars.  However, CHAC’s use of these social media platforms 
should be designed to deliver consistent messages across multiple channels, promote synergy 
across media and target efficiencies.  A number of CDC resources are available to assist CHAC 
in increasing its reach to the public through social media: 
• Health Communicator’s Social Media Toolkit (www.cdc.gov/socialmedia) 
• Guide to Writing for Social Media (www.cdc.gov/socialmedia) 
• Social Media Guidelines (www.cdc.gov/SocialMedia/Tools/guidelines) 
Dr. Marrazzo and Ms. Dempsey confirmed that an update would be placed on a future agenda 
in order for CHAC to propose potential approaches to apply social media tools and strategies to 
broaden its outreach to the public. 
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On the one hand, some members noted that CHAC should replicate the PACHA website as a 
solid model for the public to obtain accurate and up-to-date information on the activities of a 
FAC from one credible source.  For example, a Google search of “CHAC” will result in an 
outdated roster of the membership and discrepancies between the CDC and HRSA websites. 
On the other hand, other members pointed out that CHAC’s ability to replicate the PACHA 
website as a “one-stop” resource would be extremely challenging due to major differences 
between the two FACs.  For example, PACHA is chartered to advise the HHS Secretary only, 
while CHAC is chartered to advise both the CDC Director and HRSA Administrator in addition to 
the HHS Secretary.  As a result, both CDC and HRSA maintain separate CHAC websites. 
Moreover, PACHA’s base of constituents and stakeholders is limited to HIV/AIDS only, while 
CHAC’s broader base of constituents and stakeholders includes HIV, VH and STD.  To resolve 
this dilemma, CDC and HRSA should establish a common interagency website to post CHAC’s 
formal resolutions, recommendations and action items. 
Closing Session
Dr. Fenton thanked the participants for their kind remarks to him over the course of the meeting.  
He reiterated that he was honored to serve as the CHAC DFO over the past seven years.  He 
was excited about CHAC’s future directions and extended warm wishes to the members in their 
new endeavors.  However, he urged CHAC to build on and scale up the best and promising 
practices that have been established over the past seven years.  Dr. Fenton confirmed that he 
would always remain in touch with CHAC from London. 
The CHAC co-Chairs and CDC/HRSA leadership thanked the CHAC members for continuing to 
dedicate their valuable time and expertise while attending meetings and participating in the 
workgroup activities offline. 
The next CHAC meeting would be held on either June 12-13, 2013 or June 18-19, 2013 in 
Atlanta, Georgia.  The CHAC Committee Management Officers would poll the members via e-
mail to confirm the exact date and location. 
With no further discussion or business brought before CHAC, Dr. Marrazzo adjourned the 
meeting at 12:30 p.m. on December 12, 2012. 
       I hereby certify that to the best of my 
knowledge, the foregoing Minutes of the 
proceedings are accurate and complete. 
___________________    ___________________________________ 
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Date       Antigone Hodgins Dempsey, MEd, Co-Chair 
       CDC/HRSA Advisory Committee on HIV, 
       Viral Hepatitis and STD Prevention and 
       Treatment 
___________________    ___________________________________ 
Date       Jeanne Marrazzo, MD, MPH, Co-Chair 
       CDC/HRSA Advisory Committee on HIV, 
       Viral Hepatitis and STD Prevention and 
       Treatment 
